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 ABSTRACT 
 
Immunotherapy, based on the use of novel human mAbs 
endowed with antitumor or immunomodulatory activity, is an 
increasingly important strategy for cancer therapy. Monoclonal 
antibodies can be directed against Tumor Associated Antigens 
(TAAs), to inhibit their oncogenic function, or against Immune 
Checkpoints (IC), to modulate specific T cell responses against 
cancer. Furthermore, ongoing clinical trials in oncology are currently 
testing combinatorial treatments of anti-TAA and immunomodulatory 
antibodies. 
In our laboratory novel human antitumor immunoagents have 
been successfully produced against the TAA ErbB2, which is a 
Tyrosine Kinase Receptor, overexpressed in breast cancer and several 
other carcinomas. In particular, a fully human single chain antibody 
fragment (scFv), named Erbicin, able to bind to an epitope of ErbB2 
different from those recognized by the clinically validated mAbs 
Trastuzumab and Pertuzumab, was isolated by phage display selection 
on live cells. A human anti-ErbB2 “compact antibody” (100kDa) was 
also generated by the fusion of Erbicin with a human IgG1 Fc, which 
was found to efficiently inhibit ErbB2-positive tumor growth both in 
vitro and in vivo.  
As a further progress, a trispecific antibody derivative, named 
Tribody, targeting three noncompeting epitopes on the extracellular 
domain of ErbB2 was obtained by fusing 3 binding moieties derived 
from Erb-hcAb, Trastuzumab and Pertuzumab, respectively. The 
triparatopic Tribody significantly downregulates ErbB2 and inhibits 
the cell growth of tumor cells, including those resistant to 
Trastuzumab. We show here that the multiparatope tribody combines 
and potentiates the therapeutic effects of the 3 different antibodies in 1 
single antibody construct, thus allowing for the reduction of costs of 
antibody production and overcoming the limits related to 
monotherapy associated drug resistance.  
On the other hand, we performed a massive parallel screening 
of phage antibody library to obtain a large repertoire of fully human 
 immunomodulatory antibodies against several-immune regulatory 
checkpoints to be used in monotherapy or in combinatorial treatments 
for cancer therapy. We used for the first time an innovative selection 
strategy on human activated lymphocytes to generate a large 
collection of scFvs against 10 different IC, called “Immunome 
Library”, from which scFvs specifically recognizing a given receptor 
could be pulled out by subsequent affinity selection cycles on 
recombinant purified proteins used as baits. By Next Generation 
Sequencing and bioinformatic analysis we ranked individual scFvs in 
each collection and identified those with the highest level of 
enrichment. Human IgGs from three of these collections (i.e. PD-1, 
PD-L1 and LAG-3) were generated and tested for their binding and 
biological activity. In particular, they were found to specifically bind 
to their targets with high affinity, to efficiently activate T cell 
proliferation, induce cytokine secretion and inhibit in vivo tumor 
growth. Interestingly, the novel isolated mAbs have comparable or 
even better binding affinity and biological activity than the clinically 
validated anti-PD-1 mAb Nivolumab.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SOMMARIO 
L’immunoterapia, basata sull’impiego di nuovi anticorpi 
umani dotati di attività antitumorale o immunomodulatoria, 
rappresenta un’importante strategia per la terapia del cancro. Gli 
anticorpi monoclonali possono essere diretti contro Antigeni Associati 
a Tumore (TAA), allo scopo di inibire la loro funzione oncogenica, 
oppure contro proteine di superficie di cellule del sistema immunitario 
(Immune Checkpoints, IC), per modulare specifiche risposte dei 
linfociti T contro il cancro. Peraltro, sperimentazioni cliniche in corso 
nel campo dell’oncologia stanno attualmente valutando l’efficacia di 
trattamenti combinatoriali che includono anticorpi contro TAA e 
anticorpi con attività di modulazione del sistema immunitario. 
Nel nostro laboratorio sono stati prodotti con successo nuovi 
immunoagenti umani con attività antitumorale diretti contro il 
Recettore Tirosina-Chinasico ErbB2, un noto Antigene Associato a 
Tumore, iper-espresso nel carcinoma mammario ed in diversi altri tipi 
di tumore. In particolare, è stato isolato, mediante la tecnologia 
“phage display” applicata su cellule tumorali vive, un frammento 
anticorpale interamente umano, chiamato Erbicin, capace di legare un 
epitopo del recettore ErbB2 diverso rispetto a quello riconosciuto 
dagli anticorpi Trastuzumab e Pertuzumab, attualmente in uso clinico. 
Mediante la fusione di Erbicin con il dominio Fc di un anticorpo 
umano con isotipo IgG1 è stato anche generato un “anticorpo 
compatto” umano (ErB-hcAb, 100kDa) contro il recettore ErbB2, che 
si è mostrato capace di inibire efficientemente, sia in vitro che in vivo, 
la crescita di tumori ErbB2-positivi. Come ulteriore progresso, la 
fusione dei 3 domini di legame derivati da Erb-hcAb, Trastuzumab e 
Pertuzumab, ha consentito di ottenere un derivato trispecifico, 
chiamato Tribody, che riconosce 3 epitopi non competitivi sul 
dominio extracellulare del recettore ErbB2. Il Tribody triparatopico 
riduce significativamente i livelli di ErbB2 ed inibisce la crescita delle 
cellule tumorali, incluse quelle resistenti al trattamento con 
Trastuzumab. In questo lavoro di tesi mostriamo che il Tribody 
multiparatopico combina e potenzia gli effetti terapeutici dei tre 
differenti anticorpi in un solo costrutto, avendo pertanto il vantaggio 
 di consentire la riduzione dei costi di produzione rispetto a quelli di 3 
diversi anticorpi e di superare i problemi relativi alla resistenza ai 
farmaci usati in monoterapia.  
Parallelamente, in questo progetto di tesi abbiamo effettuato 
uno screening massivo di un repertorio di fagi esprimenti frammenti 
anticorpali umani allo scopo di ottenere una collezione di anticorpi 
interamente umani con attività immunomodulatoria diretti contro una 
vasta gamma di molecole chiave regolatrici del sistema immunitario, 
utili per la terapia del cancro in monoterapia o in trattamenti 
combinatoriali. A tale scopo, abbiamo usato per la prima volta una 
strategia di selezione su linfociti umani attivati allo scopo di generare 
un’ampia collezione di frammenti anticorpali a singola catena (scFvs) 
diretti contro 10 differenti IC, chiamata “Immunoma”, dalla quale 
attraverso cicli successivi di selezione su proteine ricombinanti 
purificate fosse possibile ottenere scFvs capaci di riconoscere 
specificamente ciascun recettore. Tecniche di sequenziamento di 
ultima generazione e analisi di bioinformatica ci hanno consentito di 
identificare le sequenze degli scFvs più arricchite per ciascuna 
selezione. Sono stati generati anticorpi umani a partire da tre di queste 
collezioni (i.e. PD-1, PD-L1 e LAG-3), che sono stati analizzati per la 
loro capacità di legame ed attività biologica. In particolare, essi sono 
risultati capaci di riconoscere specificamente i propri bersagli e legarli 
con alta affinità, di attivare efficientemente la proliferazione dei 
linfociti T, di indurre la secrezione delle citochine ed inibire la 
crescita tumorale in vivo. E’ interessante notare che i nuovi anticorpi 
isolati hanno un’affinità di legame ed un’attività biologica 
paragonabile o anche migliore di Nivolumab, l’anticorpo in uso 
clinico specifico per PD-1.  
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INTRODUCTION 
 
1. Immunotherapy of cancer 
Cancer immunotherapy is aimed at stimulating immune system 
against cancer and exploiting the properties of its components to 
specifically recognize the Tumor Associated Antigens (TAAs) and 
selectively attack cancer cells. Once immune cells are specifically 
stimulated against tumors, they provide a constant surveillance and 
protection against tumor relapse, due to induction of specific and 
long-lasting memory. Nevertheless, tumors escape from 
immunosurveillance by acquisition of hallmark capabilities to develop 
several different mechanisms, such as reduction of the expression of 
Major Histocompatibility Complex I (MHC I) and co-stimulatory 
ligands, and secretion of immunosuppressive factors (Koebel et al. 
2007; Papaioannou et al. 2016; Hanahan and Weinberg 2011). 
Even though some crucial discoveries started in the 70s relative to 
dendritic cells, followed by the development of the first chimeric 
antigen receptors in 1989, the cloning of the first tumor antigen in 
1991 and the successive identification of the first checkpoint 
molecule, named cytotoxic T lymphocyte-associated protein 4 (CTLA 
4) in 1995, (Steinman and Cohn 1973; Gross et al. 1989; Leach et 
al. 1996), cancer immunotherapy has particularly evolved after 2000. 
Many immunotherapeutic treatments are already in clinical 
practice as they have been approved by the Food and Drug 
Administration (FDA) for treating cancer patients (see Table 1) 
(Galluzzi et al. 2014). New classes of targeted drugs are emerging 
and many of them are already in clinical trials. 
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Table 1. Anticancer immunotherpeutics approved by FDA and 
currently in clinical use (Galluzzi et al. 2014). 
 
 
To date, the acquired knowledge on the mechanisms of anti-
tumor immune responses and the novel technological platforms 
suggest possible innovative means to induce more efficient and 
durable responses in cancer patients.  
Cancer immunotherapy is based on two main approaches: 
passive and active treatments (Figure 1) (Papaioannou et al. 2016). 
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Figure 1. Classification of active and passive cancer immunotherapy. 
The passive cancer immunotherapy approach includes the tumor specific 
mAbs, cytokines and adoptive cell transfer. The active immunotherapy 
approach includes vaccines, checkpoint inhibitors and oncolytic viruses 
(Papaioannou et al. 2016). 
 
 
The active immunotherapy approach involves anti-cancer 
vaccines (peptide, dendritic cell-based and allogeneic whole cell 
vaccines), as well as immune checkpoint inhibitors and oncolytic 
viruses. On the other hand, the best example of passive 
immunotherapy is represented by the treatment with monoclonal 
antibodies (mAbs) that have been initially used in targeted therapy 
against Tumor Associated Antigens (Papaioannou et al. 2016). 
Recently, many other antibodies targeting immune checkpoints have 
been approved by FDA for clinical use of melanoma and other cancer 
types (Galluzzi et al. 2014), due to their immunomodulatory 
functions, thus representing a novel approach for immunotherapy.  
Furthermore, the combinations of different immunotherapy 
interventions are also under investigation. The combinatorial 
approach should be elegantly orchestrated by boosting anti-cancer 
responses (PUSH), on one hand, and by neutralizing negative immune 
regulators (PULL), on the other hand (Figure 2). The combination of 
different cancer treatment modalities (e.g., chemotherapy and 
checkpoint inhibitors) and the expansion of targeted drug repertoire 
through the discovery of new targets, new drugs and new molecules 
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targeting multiple molecular pathways (e.g., pan-tyrosine kinase 
inhibitors) are the new challenges for several research groups 
(Papaioannou et al. 2016). 
 
Figure 2. The synergy between different cancer treatments. The use of 
different immunotherapeutic approaches to combine the induction of 
immune anti-cancer responses (PUSH) with the inhibition of negative 
immune regulators (PULL) (Papaioannou et al. 2016). 
 
 
1.1. Antibody-based immunotherapy against Tumor Associated 
Antigens  
The conventional anti-cancer therapy includes surgery, 
radiotherapy, and chemotherapy; however, the main limits of the latter 
two conventional treatments are represented by the absence of 
selectivity for tumor cells and by non-specific side toxic effects. The 
immunotherapy targeting cancer cells, by the use of monoclonal 
antibodies specific for TAAs overexpressed on tumor cells, represent 
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an alternative strategy to overcome these limits. For this reason, the 
immunologists have worked with the aim of inducing specific 
immune responses against cancer, by developing drugs for targeted 
therapies (Wurz et al. 2016; Kirkwood et al. 2012; Galluzzi et al. 
2014). 
The targets of these therapies can be classified into Tumor 
Specific or cancer-testis Antigens (TSAs), expressed only on tumor 
cells, and Tumor Associated Antigens, overexpressed by tumors but 
present also at low levels on normal differentiated cells from which 
the tumors arise (Wurz et al. 2016; Savage et al. 2014). 
The use of mAbs as magic bullets against these targets has 
rapidly increased over the last 40 years starting with the production of 
the first generation of therapeutic mAbs of mouse origin. 
Unfortunately, the induction by human body of human anti-
mouse antibody (HAMA) response represented an obstacle to the 
success of this approach and induced further research progresses to 
overcome these problems (Thorpe et al. 2003). Recombinant DNA 
technology allowed to replace the mouse costant domains, recognized 
by the human immune system, and responsible for HAMA response, 
with the human correspondent sequences, thus producing chimeric 
mAbs with reduced immunogenicity and improved pharmacokinetic 
and therapeutic efficacy (LoBuglio et al. 1989). Further 
improvements in recombinant DNA and cloning techniques led to 
humanized mAbs (Carter et al. 1992), obtained by inserting only the 
mouse hypervariable loops in the human V-region frameworks, thus 
further reducing the immunogenicity of the humanized antibodies.  
More recently, new strategies, such as phage display 
technology, led to the generation of human antibody libraries, to be 
used for the in vitro selection of fully human antibodies specifically 
targeting tumor cells (Frenzel et al. 2016). 
Some of the therapeutic mAbs approved by FDA for clinical use 
in cancer therapy are directed against either growth factors, such as 
vascular endothelial growth factor A, or growth factor receptors, such 
as human epidermal growth factor receptors EGFR and HER2/ErbB2. 
In addition to the specific and direct inhibitory effects on the signal 
transduction of these receptors expressed on tumor cells, therapeutic 
mAbs can also activate Antibody Dependent Cellular Cytotoxicity 
(ADCC) and Complement Dependent Cytotoxicity (CDC), or deliver 
towards tumor cells conjugated therapeutics, such as toxins or 
Introduction 
 6 
radioisotopes. More recently, bispecific antibodies able to recognize 
two antigens have been created to retarget cytotoxic T lymphocytes to 
any cell of choice (Wurz et al. 2016). 
 
 
1.2. ErbB2 and EGFR receptors as validated TAAs for breast cancer 
therapy 
Worldwide, approximately 10 million people are diagnosed 
with cancer annually and more than 6 million die of this disease every 
year (Stuart and Kleiheus 2006). In particular breast cancer affects 
one in eight women during their lives. It is the most common cancer 
in women worldwide, with nearly 1,8 million new cases (second most 
common cancer overall) diagnosed in 2013 (Fitzmaurice et al. 2015). 
A good candidate as TAA and an attractive target for 
immunotherapy is ErbB2, a Tyrosine Kinase Receptor (RTK), 
overexpressed on many carcinoma cells, with a key role in the 
development of malignancies (Slamon et al. 1989; Tagliabue et al. 
1991; Lohrisch and Piccart 2001; Gravalos and Jimeno 2008).  
ErbB2 is a receptor belonging to the ErbB family of RTKs. 
Unlike the other members of the family, ErbB2 lacks natural ligands 
and acts as the preferential heterodimerization partner for the other 
members of the family. ErbB2 overexpression on tumor cells leads to 
the activation of intracellular tyrosine kinase domain and downstream 
signalling cascades that mediate cell growth, differentiation, and 
survival (Yarden and Sliwkowski 2001; Klapper et al. 2000; Busse 
et al. 2000; Baselga et al. 2009), such as those of mitogen-activated 
protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K) 
pathways (Figure 3), with a consequent dysregulated proliferation. 
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Figure 3. EGF receptor family. Schematic representation of the Tyrosine 
Kinase Receptors EGFR, ErbB2/HER2 and HER3, their downstream 
pathways and inhibitors (Baselga J et al. 2009). 
 
 
Antitumor strategies have been well established for ErbB2-
positive tumors and indicative examples include Trastuzumab, the 
first humanized antibody approved by the FDA in 1998 for breast 
cancer therapy, and Pertuzumab approved by FDA more recently for 
combinatorial treatments with Trastuzumab and Docetaxel (Sabatier 
and Gonçalves 2014; Stebbing et al. 2000; Romond et al. 2005; 
Baselga and Swain 2010). They have different mechanisms of action 
as they bind to different epitopes in the domain II and the domain IV 
of ErbB2, respectively. Despite the success of these antibodies for 
breast cancer their clinical efficacy is still limited by resistance and 
cardiotoxicity issues. Indeed, a high fraction of patients show 
resistance to their treatment and develop cardiac dysfunction, 
frequently leading to heart failure in particular in the presence of other 
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risk factors (Slamon et al. 2001; Natha et al. 2006; Seidman et al. 
2002; De Lorenzo et al. 2018). 
To overcome the limits of Trastuzumab, novel human 
antitumor immunoagents have been recently engineered in our 
laboratory by isolation of human single-chain variable fragments 
(scFvs) through phage display technology. In particular, a human anti-
ErbB2 scFv, named Erbicin, was found to be able to selectively bind 
and inhibit ErbB2-positive tumor cells, and to recognize an epitope of 
ErbB2 different from that of Pertuzumab and Trastuzumab (Figure 4) 
(De Lorenzo et al. 2002; Troise et al. 2011). 
The following fusion of Erbicin with the Fc region of a human 
IgG1  led to  a new immunoagent construct, called Erb-hcAb (human 
compact antibody) for its compact size (100 kDa) if compared with 
the full size (155 kDa) of a natural IgG (Figure 4). This construct 
acquired the immune effector functions of the Fc domain while 
retaining the ability to diffuse more easily in the tumor masses due to 
its reduced molecular size with respect to a full size antibody. Erb-
hcAb was found to selectively bind to breast tumor cells expressing 
ErbB2 and to inhibit their growth in vitro and in vivo, by inducing 
also Antibody Dependent Cellular Cytotoxicity (ADCC) and 
Complement-Dependent Cytotoxicity (CDC) (De Lorenzo et al. 
2004). Interestingly, Erb-hcAb, differently from Trastuzumab and 
Pertuzumab, lacks cardiotoxic effects on human cardiomyocytes in in 
vitro and in vivo models (Riccio et al. 2009; Fedele et al. 2012). 
 
Figure 4. Erb-hcAb. Schematic representation of Erbicin and its derived 
compact antibody (Erb-hcAb).  
Introduction 
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Unfortunately, a high fraction of breast tumors does not 
express ErbB2. For instance, Triple-Negative Breast Cancer (TNBC), 
accounting for ~14% of all breast cancers, is characterized by the 
absence of Estrogen Receptor (ER), Progesterone Receptor (PR) and 
ErbB2, excluding the possibility of using efficacious targeted 
therapies developed against these proteins.  
On the contrary, overexpression of EGFR has been reported in 
~60% of TNBC and correlates with poor outcome. EGFR is the other 
member of the EGF tyrosine kinase receptor family, which also 
regulates the PI3K/AKT and Ras/MAPK signaling upon binding its 
ligand EGF and receptor dimerization. Increased EGFR expression 
may influence multiple aspects of tumor biology including cell 
proliferation, motility and invasiveness, and resistance to treatment 
(Figure 3) (Stommel et al. 2007; Greenall et al. 2015; Haynes et al. 
2014). 
Although more recently, also aptamers have raised increasing 
attention for cancer therapy due to their low molecular weight, lack of 
immunogenicity and ready availability. A RNA-aptamer, named CL4 
(Figure 5), able to recognize and inhibit EGFR has been recently 
generated in the laboratory of our collaborators, by an in vitro 
selection procedure: SELEX (Systematic Evolution of Ligands by 
Exponential Enrichment) (Tuerk and Gold 1990; Camorani et al. 
2018; Camorani and Cerchia 2015). The CL4 oligonucleotide 
aptamer was found able to bind and inhibit not only the human 
EGFRwt, but also the EGFRvIII mutant, expressed on the surface of 
Glioblastoma Multiforme (GBM) cancer cells, lacking most of the 
extracellular domain (Esposito et al. 2011; Camorani et al. 2015). 
Indeed, it interacts with domain IV of the receptor, which is still 
present in the EGFRvIII variant, and inhibits the autophosphorylation 
of the receptor and its downstream ERK1/2 and STAT3 pathways, 
thus affecting migration and invasion of cancer cells (Camorani et 
al. 2015). CL4 was also found able to inhibit the vasculogenic 
mimicry (VM) and tumor growth in TNBCs resistant to both 
Erlotinib and Cetuximab (EGFR-TK inhibitors), by preventing the 
EGFR-integrin αvβ3 interaction (Camorani et al. 2017). Thus, its 
use could allow for overcoming the tumor resistance to EGFR 
Tyrosine Kinase Inhibitors (TKIs). 
 
Introduction 
 10 
 
Figure 5. CL4 aptamer. Structure of the anti-EGFR CL4 aptamer 
(Esposito et al. 2011). 
 
 
1.3.  Immunotherapy targeting immune regulatory checkpoints 
The other antibody-based approach in oncology exploits the 
activation of immune system, such as the stimulation of T cells 
mediated by immunomodulatory antibodies (Peggs et al. 2009). 
 Activation of immune cells involved in anti-tumor responses 
is regulated by multiple stimulatory and inhibitory pathways on 
effector T cells that can be targeted by monoclonal agonistic or 
antagonistic antibodies. The primary targets for such interventions 
were envisaged initially to be the effector T cells, but it is becoming 
clear that, also Natural Killer (NK) cells and regulatory T (Treg) cell 
populations might be important targets.  
Understanding the complexity of immune regulation and 
tumor microenvironment has been critical to optimize the efficacy of 
the therapeutic approaches, and to develop new strategies for 
immune-based cancer therapy. The T cells have high specificity for 
their own antigen since they bear T cell receptors (TCRs) that 
specifically recognize cell-surface major histocompatibility complex 
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molecules associated with peptides derived from either endogenous or 
foreigner proteins. 
Moreover, T cells are characterized by memory, because 
primary T cell responses are generally followed by the production of 
long-lived memory T cells with accelerated kinetics of response to a 
second presentation of the antigen (Davis and Bjorkman 1988). In 
order to induce the activation of effector T cells, the single 
engagement of the MHC by the recognition of associated antigenic 
peptides, such as those derived from TAAs, by the TCR is not 
sufficient for the full activation of T cells and may render them 
anergic. A series of various stimuli generated by co-regulatory signals 
are also required to fully activate T cells and to regulate their immune 
responses. These are exerted by a series of stimulatory or inhibitory 
receptor-ligand pairs and can determine the fate of the T cell response, 
such as their activation with the subsequent differentiation into 
effector T cells, their deletion or anergy (Chen and Flies 2013). 
Translation of this concept into the clinic has led the 
researchers to focuse their efforts on the identification of antibodies 
agonistic for co-stimulatory receptors or antagonistic for inhibitory 
signals, in order to use Immune Checkpoints (ICs) to amplify the 
antigen-specific T cell responses against cancer (Pardoll 2012).  
To date, human or humanized mAbs targeting the 
immunosuppressive receptors CTLA-4 (Ipilimumab), PD-1 
(Nivolumab and Pembrolizumab), and PD-L1 (Atezolizumab, 
Durvalumab and Avelumab) have been approved for the treatment of 
several tumors, including melanoma, non-small cell lung cancer, renal 
cell carcinoma, head and neck squamous cell carcinoma, Hodgkin 
lymphoma, urothelial carcinoma, liver carcinoma, microsatellite 
instable (MI) colorectal cancer and Merkel-cell carcinoma (Brahmer 
et al. 2012; Patel et al 2017; Shultz 2017; Callahan et al. 2016).   
Despite their success, the currently approved antibodies 
against immune checkpoints (hence collectively named checkpoint 
inhibitors; CIs) are effective in only about 20-30% of the patients 
(Lee et al. 2013; Buqué et al. 2015; Pardoll 2012). As shown in 
Figure 6, new targets are emerging as co-inhibitory receptors, such as 
lymphocyte activation gene 3 (LAG-3), an immunosuppressive 
receptor expressed on activated T lymphocytes and T-regulatory 
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lymphocytes, T cell immunoglobulin and mucin-3 (TIM3), T cell 
immunoglobulin and ITIM domain (TIGIT), which are expressed on 
exhausted CD8
+
 T cells in tumors (Anderson et al. 2016; Goldberg 
and Drake 2011; Huang et al. 2004). B- and T-lymphocyte 
attenuator (BTLA) is another co-inhibitory receptor whose expression 
is induced during activation of T cells, leading to inhibition of human 
CD8
+
 cancer specific T cells (Watanabe et al. 2003). Similarly, some 
agonistic antibodies recognizing co-stimulatory receptors have 
reached the clinical stage such as those specific for OX40 (CD134), a 
secondary co-stimulatory immune checkpoint molecule that prevents 
premature death of activated lymphocytes, and 4-1BB (CD137) 
expressed on activated CD4
+
 and CD8
+
 T lymphocytes whose 
crosslinking enhances T cell proliferation, IL-2 secretion, survival and 
cytolytic activity. Other co-stimulatory proteins that are considered 
good targets for antibody-mediated immunotherapy are inducible T 
cell costimulator (ICOS), which is an immune checkpoint protein 
belonging to the CD28-superfamily that is expressed on activated T 
cells, and CD27, a member of the tumor necrosis factor receptor 
superfamily, which is required for generation and long-term 
maintenance of T cell immunity (Chen and Flies 2013; Sanmamed 
et al. 2015; Wen et al. 2002; Sasso et al. 2018). 
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Figure 6. Potential immunomodulatory targets for monoclonal 
antibody-based therapy. The interaction between inhibitory receptors, such 
as CTLA-4, PD-1, BTLA, LAG-3, TIGIT, TIM-3 with their ligands leads to 
an inhibition of the T cell activation (red arrows). Co-stimulatory receptors 
such as CD28, ICOS, 4-1BB, OX40, CD27, on the contrary, enhance the 
effector function of T cells (green arrows). 
 
 
Antibodies against different immune checkpoint receptors can 
also be combined to achieve additive or synergistic activity, 
potentially translating into a better efficacy. Proof of concept for this 
approach was provided by the finding of increased efficacy of the 
Ipilimumab and Nivolumab combination versus monotherapy in the 
treatment of metastatic melanoma (Mahoney et al. 2015; Larkin et 
al. 2015). A numerous clinical trials with approved or novel 
antibodies against immune checkpoints used in monotherapy or in 
combination with other biologics or small molecules are being carried 
out worldwide.  
A new goal is represented by the generation of a complete 
repertoire of fully human antibodies specific for all these T cell 
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checkpoint modulators, so that they can be tested in all the possible 
combinatorial treatments (Sasso et al. 2018). 
 
 
 
1.4. Generation of a human repertoire of mAbs for cancer therapy 
by Phage Display Technology 
To obtain a repertoire of fully human immunomodulatory mAbs 
against several targets to be used in monotherapy or in combinatorial 
treatments with other anti-tumor drugs for cancer therapy, innovative 
strategies based on the well-known phage display technology have 
been considered in our laboratory.  
Phage display is a precious technology that enabled to overcome 
the disadvantages of humanized mAbs, such as immunogenicity and 
low efficiency to penetrate tumor masses due to their large size (155 
kDa), by producing fully human single chain variable fragments of 
antibodies and easily selecting them by affinity procedures. 
The scFv is the smallest portion of the immunoglobulin, which 
retains the antigen-binding ability. Indeed, an antibody in the scFv 
format consists of variable regions of heavy (VH) and light (VL) 
chains, joined together by a flexible peptide linker, with a molecular 
weight of 27 kDa. Thanks to their low molecular weight and their 
retained property to bind to the antigen, the scFvs can be exploited in 
phage display technology to be expressed on the phage as fusion 
proteins with a protein of the phage coat, and to be selected for their 
binding to the targets (Ahmad et al. 2012).  
Indeed, phage display is a strategy based on the expression of 
foreigner (poly)peptides on the surface of filamentous bacteriophages. 
This strategy was introduced in 1985, by George P. Smith, who 
demonstrated that the fragment of a protein could be expressed in a 
native conformation on the phage in order to be immunologically 
recognized by antibodies, with no significant effects on life cycle and 
infectivity of the phages (Bazan et al. 2012).  
The gene encoding each scFv is packed inside the virion as a 
single-stranded DNA and the corresponding encoded protein is 
expressed as a fusion product with the pIII protein of the phage coat 
(Figure 7).  
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Figure 7. Schematic representation of scFv expressed as a fusion 
product with the pIII protein of the phage coat. 
 
 
 The phage display technology is based on the generation of 
libraries containing up to 10
10
 different variants, that can be used in a 
screening process to select antibodies against almost unlimited array 
of biological (including human self-antigens) and non-biological 
targets (such as toxic molecules). In order to identify the scFvs which 
specifically bind to the target, this technology allows for panning 
either on targets immobilized on solid support or expressed on the cell 
surface, by removing from the whole repertoire the non-binder clones 
by using affinity selection techniques. 
In our laboratory a large number of anti-tumor or other anti-
receptors scFvs have been successfully isolated by panning human 
scFv libraries either on purified proteins or on live cells expressing the 
targets on their surface (De Lorenzo et al. 2002; Palmieri et al. 
2015; Paciello et al. 2016). 
In the present project we tailored phage display to the 
generation of a complete repertoire of fully human antibodies 
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recognizing several different immune checkpoints. As shown in 
Figure 8, we applied for the first time a novel untested strategy for 
rapid, parallel screening of phage displayed antibody libraries by 
directly panning for the first time on activated human lymphocytes. 
This novel approach allows for the selection of antibodies recognizing 
the receptors in their native conformation, as that presented on the cell 
membrane, and to obtain a productive selection of several phage 
clones against multiple targets in one single panning.  
As a proof of concept of the quality/potency of the binders 
identified by this approach, we generated fully IgGs from three of 
these collections i.e. PD-1, PD-L1 and LAG-3 (Sasso et al. 2018). 
These three targets were chosen, as antibodies useful for biological 
assays and specific for them have been already developed by 
demonstrating therapeutic benefits, as described in the following 
paragraph. 
 
Figure 8. Strategy of scFvs selection by phage display against immune 
checkpoints. The phages were incubated with activated lymphocytes after a 
subtractive step on untreated lymphocytes in order to select specific phages 
for receptors expressed upon activation. The screening of enriched clones 
was performed by Next Generation Sequencing, and the identified scFvs 
were then converted into IgG4. 
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1.5. Programmed cell death receptor-1 (PD-1); Programmed Death 
Ligand-1 (PD-L1); Lymphocyte Activation Gene-3 (LAG-3) and 
their relative antibodies in use or clinical development 
 PD-1 is an immune checkpoint firstly identified in lymphoid 
cell lines undergoing programmed cell death. PD-1 is expressed on 
activated T-cells, B-cells, dendritic cells (DCs) and monocytes 
(Figure 9). The role of PD-1 on T-cells is to limit the activity of T-
cells in peripheral tissues during inflammatory responses and to 
inhibit autoimmune responses. Its expression is induced when T cells 
become activated; therefore, when engaged by one of its ligands, such 
as PD-L1, PD-1 inhibits kinases that are involved in T cell activation 
(Pardoll 2012). This inhibition mechanism mediated by PD-1 can be 
exploited by the tumor cells expressing its ligand to neutralize the 
antitumor response of T cells (Haile et al. 2013). 
 
Figure 9. Schematic representation of PD-1/PD-L1 interaction and 
downstream effects. The interaction of PD-L1 or PD-L2 with PD-1 may 
induce T cell suppression.  
 
 
Since, the interaction of PD-1, expressed on the surface of 
activated T cells, and PD-L1 on the surface of tumor cells results in 
immunosuppression, the interference mediated by an antibody 
specific for PD-1 could be a suitable strategy to reduce the 
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suppression of effector T cells. Two monoclonal antibodies targeting 
PD-1 have been already approved by the FDA: Pembrolizumab 
(Lambrolizumab) a humanized antibody firstly approved in 2014 to 
treat patients with unresectable or metastatic melanoma after 
treatment with Ipilimumab, and then approved in 2017 to treat also 
locally advanced or metastatic urothelial carcinoma (Robert et al. 
2014; Barnhart 2015; Shultz 2017), and Nivolumab, a fully human 
mAb currently in clinical use for the therapy of Hodgkin lymphoma, 
unresectable or metastatic melanoma, metastatic renal cell carcinoma 
and non-small cell lung cancer (NSCLC) (Raedler  2015; 
Kazandjian et al. 2016; Janice 2017). 
PD-L1 also acts as an inhibitor of human T cell responses, as 
the interaction of PD-L1 with PD-1 on activated T cells results in 
immunosuppression and tumor immune escape (Assal et al. 2015). 
PD-L1 is expressed on the surface of tumor cells (Figure 9) and its 
level was found increased in patients with cancer, likely because its 
expression is inducible by interferon γ (IFN-γ). 
A number of antibodies targeting PD-L1 are in clinical 
development for metastatic melanoma, Non-Small Cell Lung Cancer 
(NSCLC), Renal Cell Cancer (RCC) and bladder cancer. For instance, 
Atezolizumab is a humanized anti-PD-L1 IgG1, approved by the FDA 
for non-small cell lung cancer in October 2016 and currently 
undergoing evaluation in clinical trials for patients with other types of 
cancer, including breast cancer, renal cell carcinoma, bladder cancer, 
and small-cell lung cancer (Janice 2017). 
LAG-3, also known as CD223, is another negative regulator of 
T cell activation and homeostasis that was found to be specifically 
associated with the CD3–TCR complex following TCR engagement, 
and is therefore considered as a negative co-receptor (Figure 10). 
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Figure 10.  Schematic representation of LAG-3 and its interactions. 
LAG-3 is a transmembrane protein with structural homology to CD4, and 
four extracellular IgG domains. In addition to the membrane-bound form of 
LAG-3, it can be cleaved at the connecting peptide (CP) by metalloproteases 
to generate a soluble protein that functions as an immune adjuvant 
detectable in the serum. 
 
 
LAG-3 is expressed on activated T cells, NK cells and B cells, 
and binds with high affinity to major histocompatibility complex 
(MHC) class II molecules (Goldberg et al. 2011). It has also been 
found on TReg cells, where it plays a role in amplifying the 
immunosuppressive activity of TReg cells, and in decreasing the pool 
of memory CD4
+
 and CD8
+
 T cells (Huang et al. 2004). 
Furthermore, a monoclonal antibody targeting LAG-3, known 
as BMS-986016, is in phase 1/2a of clinical trials in monotherapy for 
advanced solid tumors (ClinicalTrials.gov Identifier: 
NCT02966548. 2018), and in combination with Nivolumab BMS-
936558, in relapsed or refractory B-cell malignancies 
(clinicaltrials.gov identifier: NCT02061761. 2018).  
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AIMS 
My PhD project was aimed at developing novel therapeutic 
approaches for cancer therapy by generating novel human antibodies.  
An innovative trispecific multiparatope Tribody, targeting 3 
nonoverlapping ErbB2 epitopes, was obtained in our laboratory in 
collaboration with a laboratory based in Lisbon. The first aim was the 
characterization of this novel Tribody by testing its ability to bind to 
tumor ErbB2-positive cells and to inhibit their growth.   
A second aim was represented by the generation of a novel 
repertoire of fully human antibodies recognizing several different 
immune checkpoints in their native conformation. In this regard, the 
phases of the research activity were the following: 
- set up of an innovative strategy based on phage display by 
performing a selection on hPBMCs; 
- identification of the most enriched scFvs clones by NGS 
and bioinformatics; 
- conversion of the selected scFvs into fully human IgG4; 
- purification and characterization of the converted 
antibodies by: testing the binding affinity of each antibody 
by ELISA assays on lymphocytes and on purified proteins; 
analysing their ability to activate T cells, and evaluating 
their antitumor effects in vivo.  
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MATERIALS AND METHODS 
 
 
Antibodies and human recombinant proteins 
 
The following antibodies were used: horseradish peroxidase 
(HRP)-conjugated anti-His mouse monoclonal antibody (Qiagen); 
HRP-conjugated anti-M13 mouse monoclonal antibody (GE 
Healthcare); anti-human LAG-3 mouse monoclonal antibody (R&D 
Systems); anti-human PD-1 human monoclonal antibody Nivolumab 
(Opdivo®); anti-human PD-L1 human monoclonal antibody (G&P 
Biosciences); HRP-conjugated anti-human IgG (Promega); HRP-
conjugated anti-human IgG (Fab’)2 goat monoclonal antibody 
(Abcam); HRP-conjugated anti-rabbit immunoglobulin from goat 
antiserum (Thermo Fisher Scientific). Trastuzumab (Roche), 
Pertuzumab (Roche) Erb-hcAb (Biotecnol) (De Lorenzo et al. 2004). 
Anti-ErbB2 rabbit monoclonal antibody and anti-pErbB2 rabbit 
polyclonal antibody were from Cell signaling Technology. 
 
The following antibodies used for FACS analyses: PE/anti-
human CD2 mouse monoclonal antibody (BioLegend), APC/anti-
human CD3 mouse antibody, PE/anti-human CD4 mouse monoclonal 
antibody, PerCP/anti-human CD8 mouse monoclonal antibody were 
all from BD Biosciences.  
APC/antihuman IgG Fc mouse antibody, APC/Cy7 anti-human 
CD366 (TIM3) mouse antibody, APC/anti-human CD272 (BTLA) 
mouse antibody, APC/anti-human CD137 (4-1BB) mouse antibody, 
APC/anti-human CD134 (OX40) mouse antibody, Brilliant Violet 
510™/anti-mouse/rat/human CD27 hamster antibody, 
APC/antihuman/mouse/rat CD278 (ICOS) hamster antibody were all 
from BioLegend. FITC/anti-human TIGIT mouse antibody (Thermo 
Fisher Scientific).  
 
The following recombinant chimeric proteins were used: 
human LAG-3/Fc; human PD-1/Fc; human PD-L1/Fc; TIM3/Fc; 
BTLA/Fc; TIGIT/Fc; OX40/Fc; 4-1BB/Fc; CD27/Fc and ICOS/Fc; 
human IgG1-Fc (all from R&D Systems) (Sasso et al. 2018). 
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Aptamers 
2’F-Py RNA aptamers (CL4 and CL4Sc), used for treatments 
in cell viability assays, were synthesized by TriLink 
Biotechonologies. CL4Sc represents the scrambled form of CL4 and 
was used as a negative control. Before each treatment, the aptamers 
were subjected to a short denaturation-renaturation step (85°C for 5 
min, on ice for 2 min, 37°C for 10 min).  
 
Bacterial Culture Media  
 
The bacterial growth was carried out in 2xTY and LB (Luria-
Bertani) culture media.  
 
 
Bacterial Strains  
 
TG1 bacterial strain was used for the production of the scFvs 
expressed as fusion proteins with pIII protein of the phage; E.Coli 
SF110 bacterial strain was used for expression of the scFvs as soluble 
proteins; E. coli DH5α (Invitrogen, Life Technologies, Paisley, UK) 
and BL21 DE3 strains (Novagen-Merck Millipore, Darmstadt, 
Germany) were used for cDNA amplification. 
 
 
Antibiotics  
 
The antibiotics used for bacterial growth and selection were 
Ampicillin (100 μg/ml) and Kanamicin (25 μg/ml). 
 
 
Cell cultures 
 
MDA-MB-231 and JIMT-1 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (GibcoTM DMEM, Thermo Fisher 
Scientific). MCF-7 cells were cultured in Modified Eagle’s Medium 
(GibcoTM MEM, Thermo Fisher Scientific). SKBR3 cells (from 
ATCC, Rockville, MD) were cultured in RPMI 1640 (Gibco BRL, 
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Life Technologies, Paisley, UK). Media were supplemented with 10% 
(vol/vol) heat-inactivated fetal bovine serum (FBS, Sigma-Aldrich), 
50 UI mL-1 penicillin, 50 μg mL-1 streptomycin (50 μg mL-1 
streptomycin), 2 nM L-glutamine all from GibcoTM, Thermo Fisher 
Scientific. MCF7 cells trasfected with the cDNA encoding the variant 
of ErbB2 lacking exon16 (Δ16Her2) were grown in minimum 
essential medium (MEM) medium (Gibco BRL) supplemented with 
10% heat-inactivated fetal bovine serum, penicillin (100 UI/mL), 
streptomycin (100 mg/mL), 2mM glutamine, 1mM sodium pyruvate, 
MEM aminoacids, and MEM nonessential aminoacids.  
 
 
Production and Purification of Tribodies 
 
Tribodies were produced by Biotecnol using its proprietary 
Trisoma platform, which includes proprietary expression and 
purification technology. This process recovers the Tribody L/Fd chain 
monomer while limiting impurities such as product variants and 
endotoxins. Tribodies were sterile filtered, aliquoted, and stored at 
70°C. The purified tribodies were analyzed and confirmed to be >95% 
L/Fd chain Tribody monomer. Low levels of endotoxins were 
confirmed by a LAL-based method. Binding of the tribodies to their 
target was confirmed in an enzymelinked immunosorbent assays 
(ELISA) with a recombinant ErbB2 extracellular domain (Riccio et 
al. 2017). 
 
 
Western Blotting analyses for the detection of ErbB2 levels on 
tumor cells 
 
The cells were plated (6
.
10
5
 cells/well) in 6-well plates and 
incubated at 37°C for 16 hours. Multiparatope and monoparatope 
tribodies (concentration of 10 nM) or each antibody (concentration of 
10 nM) were added to the cells and incubated for 30 hours at 37°C. 
The treated cells were scraped and centrifuged at 1200 rpm for 7 
minutes; the cell pellets were lysed in a buffer containing 10mM Tris-
HCl (pH 7.4), 0.5% Nonidet-P-40, and 150 mM NaCl in the presence 
of protease inhibitors (Roche). After incubation on ice for 20 minutes, 
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the extracts were clarified by centrifugation at 12000 rpm for 15 
minutes at 4°C. Protein concentration was determined by the Bradford 
colorimetric assay (Sigma-Aldrich) and Western Blotting analyses 
were performed by incubating the membranes with a commercial anti-
ErbB2 antibody, followed by the HRP-conjugated secondary 
antibody, indicated above (Riccio et al. 2017). 
 
 
Cell Viability Assays to test the effects of the multiparatope Tribody 
on tumor cells 
 
To test the effects of the multiparatope Tribody, or the 
combination of the 3 parental antibodies (Erb-hcAb, Trastuzumab and 
Pertuzumab) on tumor cell growth, SKBR3 cells were plated in 96-
well flat-bottom at a density of 1.5
.
10
4
/well and were incubated at 
37°C for 72 hours with immunoagents (5–100 nM) in the culture 
medium. Cell counts were determined in triplicate by using the trypan 
blue exclusion test. Cell survival was expressed as the percentage of 
viable cells in the presence of the tested proteins, with respect to 
untreated control cultures (Riccio et al. 2017). 
 
 
Isolation of human Peripheral Blood Mononuclear Cells 
 
Human PBMCs were isolated from blood of healthy donors by 
using Greiner Leucosep® tube (Sigma-Aldrich) following the 
manufacturer’s instructions, and frozen in a solution containing 90% 
FBS and 10% dimethyl sulfoxide (DMSO) until use. Cryopreserved 
cell vials were gently thawed out by using RPMI 1640 medium 
(GibcoTM, Thermo Fisher Scientific) supplemented with 1% L-
glutamine, 1% CTL-Wash™ (Cellular Technology Limited), and 100 
U/mL Benzonase (Merck Millipore). The collected hPBMCs were 
then washed by centrifugation, plated and incubated overnight at 37°C 
in R10 medium consisting of RPMI 1640 supplemented with 10% 
inactivated FBS, 1% L-glutamine, 50 U mL-1 penicillin, 50 μg mL-1 
streptomycin and 1% HEPES (GibcoTM, Thermo Fisher Scientific). 
After an overnight resting, the hPBMCs were collected in phosphate-
buffered saline (PBS), counted by using the Muse® Cell Analyzer 
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(Merck Millipore), resuspended at a density of 1·106 cells/mL (Sasso 
et al. 2018).  
 
 
FACS analysis of expression levels of immune checkpoints on 
hPBMCs 
 
Human PBMCs were isolated as described above. After an 
overnight incubation they were activated with Dynabeads® Human T-
Activator CD3/CD28 at a concentration of 1∙103 beads/mL 
(GibcoTM, Thermo Fisher Scientific). After 24-96 hours of 
activation, the cells were seeded in a round-bottom 96-well plate 
(1·10
6
 cells/well) and then centrifuged at 1200 rpm for 5 minutes to 
remove the supernatant. Unlabelled anti-LAG-3, anti-PD-1 
(Nivolumab) or anti-PD-L1 primary antibodies were added to each 
well at a concentration of 10 μg/mL and incubated for 90 minutes at 
room temperature by gently shaking. After extensive washes, the cells 
were stained with 100 μL of APC/anti-human IgG Fc antibody in 
FACS buffer (PBS, 1% FBS), and with 10 μg/mL of PE/anti-human 
CD2 antibody (BioLegend, San Diego) for 45 minutes at room 
temperature by gently shaking. The labeled antibodies APC/Cy7 anti-
human CD366 (TIM3), APC/ anti-human CD272 (BTLA), APC/ anti-
human CD137 (4-1BB), PE/ anti-human CD134 (OX40), Brilliant 
Violet 510™/ anti-mouse/rat/human CD27, APC/ anti-
human/mouse/rat CD278 (ICOS), FITC/ antihuman TIGIT antibodies 
were added to each well at a concentration of 10 μg/mL and incubated 
for 90 minutes at room temperature by gently shaking. After two 
washes with FACS buffer, the cells were resuspended in PBS and 
analyzed on CytoFLEX Flow Cytometer (Beckman Coulter). 
Lymphocytes were identified by analyzing the forward (FSC) versus 
side (SSC) scatter and gated to exclude debris. Healthy and apoptotic 
cell populations were identified by using viability staining 
(LIVE/DEAD solution, Thermo Fisher Scientific). The live cells only 
were considered to measure the percentage of positive cells 
corresponding to the fraction of cell populations double positive for 
both the expression of CD2 (the T-Lymphocytes lineage marker) and 
for the specific target of interest (LAG-3, PD-L1, PD-1, TIM3, 
BTLA, TIGIT, OX40, 4-1BB, CD27 or ICOS). Unstained cells or 
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cells treated with the appropriate isotype control were used as 
background control. Values were reported as the mean of at least three 
determinations (standard deviations ≤10%) (Sasso et al. 2018). 
 
 
Selection of scFv-phage clones 
 
Phagemid particles were recovered from the library by using 
the M13-K07 helper phage (Invitrogen, Thermo Fisher Scientific), as 
previously described (De Lorenzo et al. 2002). For each round of 
selection, phages (10
13
 cfu) were blocked by incubating them with 5% 
(wt/vol) Skim Milk Powder (Fluka Analytical, Sigma-Aldrich) for 30 
mins in PBS before their use. For the first round of selection, blocked 
phages (10
13
 cfu) were firstly submitted to one round of negative 
selection by incubation with untreated lymphocytes (5
.
10
6
) in 2.5% 
(wt/vol) Skim Milk Powder (Fluka Analytical, Sigma-Aldrich, USA) 
in PBS for 2 hours at 4°C by gently rotation. 
The unbound phages were collected in the supernatant by 
centrifugation at 1200 rpm for 10 minutes and then used for the 
positive selection, performed by incubating them with activated 
lymphocytes (1
.
10
6
) overnight by gently rotation at 4°C in the 
presence of 2.5% skim milk powder. For the selection of phages 
binding to CD27, BTLA and TIGIT the negative panning was not 
carried out to avoid the loss of some specific phages in the subtractive 
selection. After extensive washes with PBS, the bound phages were 
eluted from activated lymphocytes with 76 mM citric acid (pH 2.5) in 
PBS for 5 minutes, and then neutralized with 1M Tris-HCl (pH 8.0). 
The recovered phages were amplified by infecting E. coli TG1 cells to 
prepare phages for the next rounds of selection on the purified 
chimeric protein. To this aim, NuncTM polypropylene tubes (Fisher 
Scientific, Thermo Fisher Scientific) were coated with the selected 
recombinant chimeric proteins at a concentration of 20 μg/mL in a 
0.05 M NaHCO3 solution, for 72 hours at 4°C. Blocked phages were 
submitted to two following rounds of negative selection by incubating 
them in the tubes coated with rhIgG1-Fc protein for 2 hours at 4°C in 
rotation. 
Unbound phages, recovered in the supernatant, were then 
incubated in the coated tubes, prepared as described above for the 
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positive selection, overnight at 4°C in rotation, and eluted as 
described above. Alternatively, since a trypsin site is present between 
the scFv and the pIII protein of the phage coat, trypsin was used for a 
more efficient and selective elution of the binders. Briefly, after 
extensive washes with PBS, the bound phages were incubated with 50 
mM Tris-HCl (pH 8.0) buffer containing 1 mM CaCl2 for 1 hour at 
4°C in rotation, and then eluted from the chimeric proteins with 
trypsin (1μg/mL), incubated for further 15 minutes at 25°C by gently 
shaking. The reaction was then blocked by using protease inhibitors 
(Complete™ EDTA-free Protease Inhibitor Cocktail, Sigma-Aldrich). 
Phages were then collected and stored at 4°C until use (Sasso et al. 
2018). 
 
DNA fragment preparation and high-throughput sequencing 
 
For each sublibrary, obtained from each selection cycle, the 
phagemid double-strand DNAs containing the scFvs were purified 
from cultures of superinfected E. coli TG1 cells using Endo free 
Plasmid Maxi Kit (Qiagen). The full-length scFvs were excised with 
restriction enzymes BamHI and HindIII, all from New England 
Biolabs, and purified with Wizard® SV Gel and PCR Clean-Up 
System (Promega) from 1.2% agarose gel (Sasso et al. 2015). A 
second enzymatic excision was performed with NcoI and XhoI, all 
from New England Biolabs, to isolate the VHs from the previously 
purified material, and then extracted from a 1,4% agarose gel. Library 
preparations for sequencing and preliminary bioinformatic analysis of 
the data were performed at the Center for Translational Genomics and 
Bioinformatics, Hospital San Raffaele, Milano, Italy. The VHs 
extracted from sub-libraries were bar-coded by TruSeq ChIP sample 
prep kit (Illumina). A complementary scheme for bar-coding was 
implemented to obtain a deep and suitable sequencing of VH mixtures 
of several subcycles. Subcycles 2 and 3 for each target were mixed in 
a dedicated run. The first universal cycle 1 was sequenced separately 
to cover the larger complexity. The bar-coded samples were diluted to 
a final concentration of 10 pM and sequenced with 2
.
300 nt SBS kit 
v3 on an Illumina MiSeq apparatus (Sasso et al. 2018). 
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scFv recovery 
 
The clones of interest were isolated from the sublibrary at 
cycle 3 of the corresponding target. For high-ranking clones (relative 
representativeness ≥1% within cycle 3), the QuickChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies) was used to perform 
copies of clones with overlapping primers, designed within the 
corresponding HCDR3 regions, according to the procedure previously 
described (Sasso et al. 2015). Briefly, the extension reactions were 
assembled as follows: 50-250 ng of template; 2/5 μL QuickSolution 
reagent; 1 μL Pfu Ultra High-Fidelity DNA polymerase (2.5 U/μL); 5 
μL 10x reaction buffer; 1 μL dNTPmix; 125 ng forward primer; 125 
ng reverse primer; H2O to a final volume of 50 μL. The template 
DNA was removed by restriction with 1 μL of DpnI enzyme, as 
suggested by the kit provider. An appropriate amount of reaction was 
used to transform XL10-GOLD ultracompetent cells (Agilent 
Technologies) and then plated on LB/agar containing 100 μg/mL 
ampicillin. Some colonies were picked and evaluated by double 
digestion and sequencing. For low ranking clones (relative 
representativeness <1% within cycle 3), the DNA samples were 
isolated from cycle 3 by overlapping PCR. Briefly, Phusion High-
Fidelity DNA Polymerase (Thermo Fisher Scientific) was used to 
perform two PCR reactions to obtain separately VH and VL 
fragments, using primers designed within the corresponding HCDR3 
regions and in constant region of plasmid upstream and downstream 
of VH and VL. 
In a second step, the PCR fragments corresponding to each 
clone were mixed and extended to get the full scFvs. The reactions 
were assembled as follows: 150 ng of template for VH and VL 
fragments amplification and 10 ng of template (VH and VL 
fragments) for full scFv amplification; 0.5μL Phusion DNA 
Polymerase (0.02 U/μl); 10 μL 5X Phusion HF Buffer; 1 μL dNTP 
mix; 0.5 μM forward primer; 0.5 μM reverse primer; 1.5 μL DMSO; 
H2O to a final volume of 50 μL (Sasso et al. 2018). 
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Antibody production and purification 
 
The scFvs of interest were converted into whole IgG4 
antibodies by cloning the corresponding VH and VL cDNAs in the 
pEU vectors 8.2VH and 4.2VL, expressing respectively, the constant 
antibody heavy and light chains (Paciello et al. 2016). Briefly, the 
VHs and VLs were amplified by CloneAmp HiFi PCR Premix in 
standard conditions with specific primers and purified by Wizard® 
SV Gel and PCR Clean-Up System (Promega) from 1.3% agarose gel. 
In-Fusion HD cloning kit (Clontech Laboratories) was used to 
clone the VHs in BamHI and BssHII (New England Biolabs), 
linearized pEU8.2VH vector, and the VLs in ApaLI and AvrII (New 
England Biolabs), linearized pEU4.2VL vector. Stellar Competent 
Cells (Clontech Laboratories) were transformed with the obtained 
vectors, and the colonies were screened by digestion and sequence 
analysis. The vectors containing the correct DNA, prepared with an 
endotoxin-free system (EndoFree Plasmid Maxi Kit, Qiagen), were 
co-transfected in HEK293-EBNA by using Lipofectamine 
Transfection Reagent (Life Technologies, Inc.) and grown up for 
about 10 days at 37°C in chemical defined CD CHO medium (Gibco, 
Life Technologies, Inc.) supplemented with 5 mL of L-glutamine 200 
mM (Gibco, Life Technologies), 5 mL of Penicillin (100 UI/mL) and 
Streptomicyn (100 mg/mL), from Sigma-Aldirch, in 6-well plates or 
in 150 mm Corning® tissue-culture treated culture dishes. 
The conditioned media were collected, and the antibodies were 
purified by using Protein A HP SpinTrap30 (GE Healthcare Life 
Sciences). The purity of the final products was evaluated by 
SDSPAGE NuPAGE™ 4-12% Bis-Tris Protein Gels, 1.0 mm, 10-
well (Thermo Fisher Scientific) followed by the staining with 
Coomassie blue solution (Biorad) for 20 minutes and de-stained with 
7% CH3COOH and 20% Et-OH. All the antibody preparations were 
filtered with sterile 0.22 μm durapore hydrophilic filters (Millipore) 
before their use (Sasso et al. 2018). 
 
Enzyme-Linked Immunosorbent Assays (ELISA) 
To detect the surface ErbB2 levels on ErbB2-positive cells, the 
cells were harvested in nonenzymatic dissociation solution (Sigma-
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Aldrich), washed and plated in 96-well round-bottom microtiter plates 
(2
.
10
5
 cells/well). Then, the cells were incubated in the absence or 
presence of increasing concentrations of each Tribody (3–100 nM) or 
other anti-ErbB2 antibodies (in ELISA buffer PBS/BSA 3%) at room 
temperature for 2 hours (Riccio et al. 2017). 
To confirm the binding specificity of the purified 
immunomodulatory mAbs, ELISA assays were performed on 
chimeric proteins (coated at 5 μg/mL on microplates), tumor cells 
(PD-L1-positive breast cancer MDA-MB-231 or PD-L1-negative 
breast cancer MCF7 cells), and untreated or activated hPBMCs. 
The ELISA assays on coated chimeric protein were performed 
by coating NuncTM flat bottom 96-well plates (Thermo Fisher 
Scientific) with 5 μg/mL rhPD-L1, rhPD-1 and rhLAG-3 recombinant 
proteins in a solution of 0,05 M NaHCO3 for 72 hours at 37°C. After 
blocking of the coated 96-well plates with 5% nonfat dry milk in PBS 
for 1 hour at 37°C, the purified mAbs were added at increasing 
concentrations (10-200 nM) to the plates in 2.5% nonfat dry milk in 
PBS and incubated for 2 hours at room temperature by gently shaking.  
Cell ELISA assays were performed by plating the cells in 
round-bottom 96-well plates (2·105 cells or 2·105 lymphocytes for 
each well) and incubating them with increasing concentrations (0.5-
200 nM) of mAbs in 2.5% nonfat dry milk for 2 hours at room 
temperature with gentle agitation (Sasso et al. 2018). 
After the incubation with the primary antibodies extensive 
washes were carried out with PBS, then the plates were incubated 
with an appropriate HRP-conjugated antibody for 1 hour at room 
temperature, washed again and incubated with 3,3’,5,5’-
tetramethylbenzidine (Sigma-Aldrich) reagent for 10 min before 
quenching with an equal volume of 1 N HCl. Absorbance at 450 nm 
was measured by the Envision plate reader (Perkin Elmer, 2102). 
Binding values were reported as the mean of at least three 
determinations obtained in three independent experiments.  
The Kd values were calculated by elaboration of ELISA 
binding curve analyses by Prism (Graphpad) tool according to the 
following model: Y=Bmax*X/(Kd+X) + NS*X + Background. Bmax 
is the maximum specific binding in the same units as Y; Kd is the 
equilibrium binding constant, in the same units as X, and it is the 
ligand concentration needed to achieve a half-maximum binding at 
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equilibrium; NS is the slope of non-specific binding in Y units divided 
by X units; background is the amount of nonspecific binding with no 
added ligand. 
 
 
Competitive ELISA assays 
 
In order to investigate the ability of the selected PD-L1_1 and 
PD-L1_2 antibodies to compete in the PD-L1/PD-1 or PD-L1/B7.1 
binding, competitive ELISA assays were performed by testing the 
binding of each biotinylated chimeric protein (PD-1/Fc or B7.1/Fc) to 
PD-L1 in the absence or in the presence of the unlabelled competitive 
antibodies. To this aim, a NuncTM flat-bottom 96-well plate was 
coated with 200ng/ml of PD-L1 recombinant protein in 0.005M 
NaHCO3 solution for 72 hours at 4°C. Then, the PD-L1 coated plate 
was pre-incubated with the competitor PD-L1_1 and PDL1_2 
antibodies (at 10:1 M/M excess ratio), and then further treated with 
the biotinylated PD-1 or B7.1 chimeric proteins, which were added to 
the plate at the same concentrations of the competitive antibodies 
(2μg/ml corresponding to 2.4
.
10
12
 molecules/well). For the detection 
of bound biotinylated proteins, HRP-conjugated Streptavidin (Biorad) 
was added to the plate, whereas an anti-human antibody was used in 
parallel assays for the detection of bound anti-PD-L1 antibodies. 
To determine whether the novel anti-PD-1 mAbs recognize 
different epitopes from that recognized by Nivolumab, competitive 
ELISA assays were performed on plates coated with PD-1/Fc 
chimeric protein (5 μg/mL). After blocking with 5% Nonfat Dry Milk 
in PBS, the coated 96-well plate was pre-incubated for 2 hours with 
saturating concentrations of each unlabelled mAb (400 nM) in 2.5% 
Nonfat Dry Milk in PBS in agitation at room temperature. After 
extensive washes with PBS, increasing concentrations of biotinylated 
Nivolumab mAb were added. For the detection of the binding, the 
plate was incubated with HRP-conjugated Streptavidin for 30 minutes 
in agitation at room temperature, washed again and analyzed as 
described above (Sasso et al. 2018). 
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Lymphocyte proliferation assays by FACS analysis 
For the staining, pre-warmed 0.1% bovine serum albumin/PBS 
solution containing CFDA-SE (Vybrant® Cell Tracer Kit, 
InvitrogenTM, Thermo Fisher Scientific) at a concentration of 10 μM 
was used to resuspend hPBMCs at a density of 1·106 cells/mL, that 
were incubated at 37°C for 10 minutes. Ice-cold R10 medium was 
then used to permeabilize the cells by incubating on ice for an 
additional 5 min. The cells were then washed three times with PBS. 
Between the second and the third wash, the cells were incubated at 
37°C for 5 minutes to allow for the complete removal of excess of 
CFDA-SE. After the last wash and centrifugation at 1200 rpm for 10 
minutes, the cells were resuspended at a density of 1·106 cells/mL in 
R10 and plated into a 48-well plate (1·106 cells/well). The 
lymphocyte proliferation assays were performed by incubating the 
plated lymphocytes with 2.5 μg/mL phytohemagglutinin-L (PHA-L, 
Roche), in the absence or in the presence of the selected anti-LAG-3, 
anti-PD-1 or anti-PDL1 mAbs (10 μg/mL). The plates were then 
incubated at 37°C for 5 days. At the end of treatment, each sample 
was recovered, resuspended in 100 μL of PBS and transferred into a 
round-bottom 96-well plate. First, the cells were incubated with violet 
LIVE/DEAD solution (Thermo Fisher Scientific) for 30 minutes at 
4°C. After several washes, the samples were further incubated with 
the anti-human CD3 (APC), anti-CD4 (PE) and anti-CD8 (PerCP) 
antibodies (10 μL/sample) for 1 hour at 4°C. Finally, the cells were 
extensively washed, resuspended in 200 μL of PBS and transferred 
into 5 mL polystyrene round-bottom tubes (BD Biosciences) for 
acquisition at CytoFLEX Flow Cytometer (Beckman Coulter) (Sasso 
et al. 2018). 
  
Effects of novel antibodies on the production of cytokines by 
stimulated hPBMCs 
 
hPBMCs (1·106 cells) were cultured and stimulated with 2.5 
μg/mL PHA-L or 50 ng/ml Staphylococcal enterotoxin B (SEB, 
Sigma-Aldrich) for 18, 42 and 66 hours, in the absence or in the 
presence of the selected anti-LAG-3, anti-PD-L1 and anti-PD-1 mAbs 
(20 μg/mL) or an isotype control antibody, used as a negative control. 
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Nivolumab and Atezolizumab (InvivoGen, hpdl1-mab 9-1) were 
tested as a positive control in parallel assays, in the same conditions. 
The levels of IL-2 or IFNγ in cell culture supernatants were measured 
by ELISA assays (all from DuoSet ELISA, R&D Systems), according 
to the manufacturer's recommendations. Concentration values were 
reported as the mean of at least three determinations in five 
independent experiments performed by using lymphocytes from 5-8 
healthy donors (Sasso et al. 2018). 
 
Lymphocyte proliferation ELISA assay based on the measurement 
of BrdU incorporation after co-culture with PD-L1 positive tumor 
cells 
Since the MDA-MB-231 breast tumor cells express high levels 
of PD-L1 molecules on their surface, we tested the ability of the anti-
PD-L1_1 and PD-Ll_2 antibodies to suppress the inhibitory action of 
the PD-1/PD-L1 interaction on lymphocyte proliferation when the two 
cell types are co-cultured. To this aim we performed a colorimetric 
immunoassay, by using the Cell Proliferation ELISA BrdU kit 
(Roche® Applied Science GmbH), according to the manufacturer’s 
recommendations, for the quantification of the lymphocyte 
proliferation. Briefly, MDA-MB-231 (1
.
10
4
 cells/well) were 
previously treated for 30 min at 37°C with mitomycin C (50 μg/ml), 
which inhibits the DNA synthesis of tumor cells, thus allowing for the 
specific evaluation of lymphocyte proliferation. Then, the tumor cells 
were co-cultured with hPBMCs in the absence or in the presence of 
increasing concentrations of anti-PD-L1 antibodies (50, 100 and 200 
nM) for 72 hours at 37°C. After an additional incubation of 24 hours 
with BrdU labelling solution, the cells were fixed and the DNA was 
denatured to improve the accessibility of the BrdU incorporated in 
newly synthesized DNA for detection with the HRP-conjugated anti-
BrdU antibodies. The bound antibodies were detected by the addition 
of TMB and quantified spectrophotometrically by measuring the 
absorbance at 450 nm. The increase of the absorbance values correlate 
with DNA synthesis, and thus allow for quantification of proliferating 
cells (Sasso et al. 2018). 
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In vivo studies 
 
Six-week old female BalBC mice (Envigo) were used for in 
vivo studies. Mice were implanted subcutaneously on the right flank 
with 2
.
10
5
 CT 26 tumor cells (day 0), and then treated intra-
peritoneally with 200 μg of α-mPD-L1 (BioXcell, clone 10F.9G2), α-
mPD-1 (BioXcell, clone RMP114), PD-1_1 or PD-L1_1 at day 3, 6 or 
10. Tumor growth was measured by caliper every 3-4 days using the 
formula LxW2/2 (L as the largest and W the smallest diameter of the 
tumor). Animals were sacrificed as soon as signs of distress or a 
tumor volume above 2000 mm
3
 occurred (Sasso et al. 2018). 
 
Statistical analyses 
 
Error bars were calculated on the basis of the results obtained 
by at least three independent experiments. Analyses on activated 
lymphocytes were performed by using samples of hPBMCs obtained 
by at least three different donors. For these studies, differences 
between groups were assessed by Student’s t-test. Statistical 
significance was defined as p<0.05.
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RESULTS 
 
1. Immunotherapy based on novel human 
immunoagents specific for TAAs 
 
1.1 In Vitro Effects of the Triparatopic Targeting Tribody on 
Tumor Cell Growth 
 
Combinations of antibodies targeting different epitopes on the 
same Tyrosine Kinase receptor extracellular domain are often able to 
downregulate oncogenic activity more efficiently than single mAbs by 
increasing internalization and degradation of the receptor, as well as 
by preventing the activation of the tyrosine kinase activity (Drebin et 
al. 1988; Friedman et al. 2005; Scheuer et al. 2009). 
The hypothesis was formulated in our laboratory that 
trispecific molecules, including binding sites for three different 
epitopes of the same receptor, can bind almost the double amount of 
receptors and can do that in such a way that a more complex and 
dense matrix is formed (Figure 11F) (Riccio et al. 2017). 
To test whether the simultaneous targeting of 3 
nonoverlapping ErbB2 epitopes in a trispecific molecule, showed 
more efficient antitumor properties than that of a monospecific 
trivalent molecule with 3 identical binding sites recognizing one 
epitope only, different tribodies were produced. Tribodies are novel 
biological constructs, made up of a Fab fused to two scFvs, as they 
consist of a light chain (L) containing an N-terminal variable (VL) 
domain and a C-terminal constant (CL) domain and a Fd chain 
including 2 N-terminal variable (VH) and C-terminal constant (CH1) 
domain. Both the L and Fd chains are extended at their C-termini with 
a flexible linker joining each of them with an additional scFv (Figure 
11). 
Three different tribodies were designed and constructed in 
collaboration with a research group (based in Lisbon): a trispecific 
multiparatope Tribody (Tb), called Tb-TPE, which targets the 3 
different epitopes recognized by Trastuzumab (T), Pertuzumab (P), 
and Erbicin (E), respectively. As controls, their 3 corresponding 
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trivalent monoparatope tribodies, Tb-TTT, Tb-PPP, and Tb-EEE were 
produced (Figure 11D) (Riccio et al. 2017). 
 
 
 
Figure 11. Triparatopic Tribody specific for ErbB2. A: Schematical 
representation of ErbB2: the epitopes recognized by the antibodies are in 
domain I (Erb-hcAb), domain II (Pertuzumab), and domain IV 
(Trastuzumab) of the ErbB2 extracellular domain. B: Tribodies are stable 
and flexible antibody derivatives with a long span of each consisting of a 
recombinant fusion of a Fab fragment with 2 different scFv fragments at 
their C-terminus.The model shown was based on a mouse anti-chicken egg 
lysozyme Fab (PDB 1FDL) and scFv (PDB 2ZNX) using PyMOL. C: 
Tribodies are constructed by genetic fusion of the genes for either the Fab 
Fd-chain or L-chain with the genes of 2 distinct scFv molecules. D: The 
triparatopic Tb-TPE (trivalent Tribody made up of 3 binding sites 
recognizing distinct nonoverlapping epitopes of ErbB2, derived from Erb-
hcAb (in black), Pertuzumab (in gray), and Trastuzumab (in light gray) was 
compared with the trivalent monoparatopic equivalents Tb-TTT, Tb-PPP, 
and Tb-EEE. The schematic model of a possible aggregation induced by 3 
pairs of bivalent monoparatopic mAbs (E) or by triparatopic molecules (F) 
(Riccio et al. 2017). 
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Binding assays to evaluate and compare the ability of the 
monoparatopic versus triparatopic Tribodies to bind to ErbB2-positive 
tumor cells were also previously carried out by my colleagues in our 
laboratory. A positive correlation between the levels of expression of 
ErbB2 on a cell line and the binding of the tribodies to the cells was 
observed, thus confirming their binding specificity for the target. 
Moreover, the triparatopic tribody showed the highest affinity for all 
the cell lines tested (data not shown) (Riccio et al. 2017). 
Furthermore, the multiparatope and monoparatope tribodies 
were also previously tested by my colleagues to evaluate their effects 
on a panel of ErbB2-positive tumor cells. With this aim the cells were 
incubated for 72 hours in the absence or in the presence of increasing 
concentrations of each immunoagent and cell survival was evaluated 
by trypan blue cell counts. The multiparatope tribody Tb (TPE) 
strongly inhibited the growth of all the tumor cells tested, including 
those resistant to Trastuzumab, differently from Tb (TTT). As for the 
tumor cells sensitive to Trastuzumab, the triparatope tribody showed a 
stronger cytostatic activity at low concentrations, than that of 
monoparatope tribodies (data not shown, Riccio et al. 2017). 
 
 
1.2 Receptor Downregulation is Enhanced by Triparatopic Tribody  
 
To test whether the effects of Tb (TPE) on tumor cell growth 
was due to its ability to downregulate the levels of ErbB2 more 
efficiently then the monoparatope tribodies, mammary SKBR3 tumor 
cells were treated with multiparatope or monoparatope tribodies for 
different time intervals (16, 30, 48, 60, and 72 hours). Cells were then 
lysed and the level of ErbB2 was evaluated by western blotting 
analysis with a commercial anti-ErbB2 antibody. The level of ErbB2 
in SKBR3 cells treated with the multiparatope Tribody Tb-TPE was 
significantly downregulated after 30 hours, while the monoparatope 
tribodies did not downregulate ErbB2 so efficiently (Figure 12). 
Similar results were obtained also for the longer time intervals used 
(data not shown) (Riccio et al. 2017). 
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Figure 12. Effects of the tribodies on ErbB2 downregulation on tumor 
cells. A: Western blotting analyses with an anti-ErbB2 antibody of extracts 
from SKBR3 tumor cells untreated (control) or treated with the indicated 
tribodies for 30 hours at 37° C.  The intensity of the bands was normalized 
with actin used as standard protein and reported as percentages of the ErbB2 
levels detected in untreated cells (lower panel). B: Cell ELISA assay with an 
anti-ErbB2 antibody to detect the surface receptor on SKBR-3 tumor cells 
treated with the indicated tribodies for 30 hours at 37°C. The absorbance 
values, measured by a microplate reader, are reported as percentage of the 
surface ErbB2 levels with respect to those detected in untreated cells 
(control). The values were reported as the mean of at least three 
determinations obtained in three independent experiments. Error bars 
depicted means ± SD (Riccio et al. 2017).  
 
 
 
As control, SKBR-3 cells were also treated with the 
multiparatope Tribody in the absence or presence of an excess (10:1 
M/M) of each Fab (Erb-Fab, Tra-Fab, Per-Fab) to confirm that all the 
3 epitopes are needed to efficiently downregulate ErbB2 levels. 
Indeed, the downregulation of ErbB2 in the cells treated with the 
multiparatope Tribody is significantly inhibited only by the 
combination treatment with all 3 Fabs, but it is not affected by the 
cotreatment with 1 Fab only (data not shown) (Riccio et al. 2017). 
We also compared the effects of the multiparatope Tribody on 
downregulation of ErbB2 in SKBR3 cells with those resulting from 
the effects of treatment with the combination of the 3 antibodies 
targeting different epitopes (Erb-hcAb, Trastuzumab, 2C4 or 
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Pertuzumab). As shown in Figure 13A, the multiparatope Tribody 
downregulates ErbB2 more efficiently than the combinatorial 
treatment of the 3 different antibodies. To test whether these effects 
on ErbB2 downregulation were correlated to those on cell viability, 
the same combinatorial experiments were repeated as described 
above, and the cell survival was measured by trypan blue cell counts. 
The multiparatope Tribody inhibits the tumor cell growth more 
efficiently than each combinatorial treatment, thus suggesting that its 
more potent effect on receptor degradation leads to a more potent 
antitumor effect (Figure 13B). These results strongly indicate that the 
multiparatope Tribody combines and enhances the therapeutic effects 
of the 3 different antibodies in 1 single antibody construct (Riccio et 
al. 2017). 
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Figure 13. Comparison of the effects of the trispecific Tribody with 
respect to the combination of the 3 parental antibodies on ErbB2 
downregulation and cell viability. A: Western blotting analysis with an 
anti-ErbB2 antibody of extracts from SKBR3 cells treated with the 
multiparatope Tribody or with the combination of the indicated antibodies. 
The intensity of the bands was normalized to actin and reported as 
percentages of the ErbB2 levels detected in untreated cells (lower panel). B: 
Viability of SKBR3 cells treated with the multiparatope Tribody or with the 
combination of the indicated antibodies is reported as a percentage of cell 
viability of untreated cells. The values were reported as the mean of at least 
three determinations obtained in three independent experiments. Error bars 
depicted means ± SD (Riccio et al. 2017). 
 
 
 
We further evaluated whether the levels of ErbB2 were 
downregulated in Trastuzumab-resistant MCF7-HER2Δ16, and JMTI-
1 cell lines. MCF7-HER2Δ16 is a cell line expressing the variant of 
HER2Δ16, encoding a receptor lacking exon 16, the absence of which 
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determines constitutive active dimers with transforming activity 
(Mitra et al. 2009). JIMT-1 cells express high levels of MUC4, 
which masks the epitope recognized by Trastuzumab (Nagy et al. 
2005). 
These cells were incubated in the absence or in the presence of 
10 nM triparatope (Tb-TPE) or monoparatope tribodies for 30 hours 
at 37°C. In a parallel assay, SKBR-3 cells were used as a positive 
control. 
As shown in Figure 14, the level of ErbB2 in MCF7-
HER2Δ16 cells treated with the triparatope Tribody Tb-TPE is 
dramatically reduced, whereas it is not affected by the treatment with 
monoparatope tribodies, with the only exception of the treatment with 
Tb-EEE. Similar results were also obtained with the triparatope 
Tribody Tb-TPE on JIMT-1 cells, which were found to be sensitive to 
treatment with Tb-EEE but unaffected by Tb-TTT, as expected by 
taking into account the resistance of these cell lines to Trastuzumab.  
To confirm these results with another experimental approach 
that allows for the detection of the levels of the receptor expressed 
only on the cell surface, we repeated the experiment mentioned above 
by performing cell ELISA assays with an anti-ErbB2 mAb on both 
Trastuzumab-resistant MCF7-HER2Δ16, JMTI-1 or Trastuzumab-
sensitive SKBR3 tumor cells, previously treated in the absence or in 
the presence of 10 nM triparatope (Tb-TPE) or monoparatope 
tribodies for 30 hours at 37°C. The results are comparable to those 
obtained by western blotting analyses (Figure 14), and strongly 
indicate that Tb-TPE reduces the density of the cell surface receptor 
on all the cell lines tested more efficiently with respect to the 
monoparatope tribodies (Riccio et al. 2017). Thus, we can conclude 
that a triparatope Tribody specific for ErbB2 has the potential to 
become a best-in-class therapeutic to address monotherapy drug 
resistance and tumor heterogeneity. 
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Figure 14.  Effects of the tribodies on ErbB2 downregulation on tumor 
cell lines. On the left, Western Blotting analyses with an anti-ErbB2 
antibody of extracts from SKBR-3 (A), MCF7-HER2Δ16 (B), JIMT-1 (C) 
tumor cells untreated (control) or treated with the indicated tribodies for 30 
hours at 37° C.  The intensity of the bands was normalized with actin used 
as standard protein and reported as percentages of the ErbB2 levels detected 
in untreated cells. On the right, cell ELISA assays with an anti-ErbB2 
antibody on SKBR-3 (D), MCF7-HER2Δ16 (E), JIMT-1 (F) tumor cells 
treated with the indicated tribodies for 30 hours at 37°C. The absorbance 
values measured by a microplate reader are reported as percentage of the 
surface ErbB2 levels detected in untreated cells. The values were reported as 
the mean of at least three determinations obtained in three independent 
experiments. Error bars depicted means ± SD (Riccio et al. 2017). 
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2. Immunotherapy based on immunomodulatory mAbs 
 
 
2.1 Selection of scFvs on activated human PBMCs 
Our goal was the generation of a repertoire of human antibody 
against immune checkpoints. Since many IC are expressed on the 
surface of T lymphocytes and their expression is increased when T 
cells are exposed to antigen-dependent or independent stimuli, we 
sought to use unfractionated human peripheral blood mononuclear 
cells (hPBMCs) to screen libraries of human scFvs. To optimize the 
selection process, we first evaluated the kinetics and level of 
expression of 10 different IC (Table 2) after in vitro activation with 
anti-CD3/CD28 beads. As shown in Table 2, peak expression 
measured by flow cytometric analysis varied between the different 
immunomodulators; however, the majority of them reached maximal 
levels of display after 96 hours of stimulation. After 96 hours of 
stimulation, all IC were well expressed in more than 50% of the gated 
population except BTLA, which reached a maximum of display in 
40% of the population, and TIGIT, which only slightly increased its 
expression levels. Similar results were obtained by repeating the same 
treatment on the same hPBMC sample and on hPBMCs from different 
donors (not shown). In order to clarify the determination of expression 
(%) of each target on human lymphocytes, reported in Table 2, as 
well as gating strategy, representative fluorescence-activated cell 
sorting (FACS) analyses of the time course of activation for the 
indicated immune checkpoints on human lymphocytes have been 
reported in Figure 15. On the basis of this analysis, we have chosen 
96 hours as the time point for the activation of lymphocytes to be used 
for the selection of the human scFv library. The strategy of using 
activated lymphocytes in the first panning was devised to ensure 
targeting of proteins with their native conformation, as that presented 
on the cell membrane, and to obtain a productive enrichment of 
several phage clones against multiple targets in one single shot, thus 
reducing also the time requested for multiple parallel selections. 
To this aim about one million phage particles were selected by 
panning the library (1
.
10
12 
different phages) on activated hPBMCs as 
described in the Materials and Methods section (selection cycle 1). A 
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negative panning on untreated lymphocytes was performed for some 
selections to remove from the repertoire all the non-specific phages 
that recognize common antigens on the cell surface (see Materials and 
Methods). For the isolation of scFvs against some targets also 
expressed at similar levels on untreated lymphocytes, such as CD27, 
BTLA and TIGIT, the negative panning was not carried out to avoid 
the loss of some specific phages in the subtractive selection. 
The pool of phages obtained from cycle 1 potentially 
represented a large collection of binders to many different IC, 
henceforth referred to as the ‘Immunome Library’. To facilitate the 
identification of molecules recognizing specific receptors, we used a 
panel of 10 recombinant proteins to further affinity select the 
Immunome Library. With the aim of developing a universal protocol 
for the selection of antibodies to cell surface displayed proteins, we 
performed 10 different parallel selections with two subsequent cycles 
of selection on recombinant Fc-fusion proteins. This strategy 
represented a compromise between efficiency of selection and 
generation of IC-specific repertoires with significant diversity to 
allow for the identification of antibodies binding to different regions 
of the target IC and with different biological activities. In parallel, a 
conventional selection performed by three panning cycles on the 
purified protein only was carried out for LAG-3/Fc, followed by 
ELISA in order to do a comparison with the novel proposed approach 
(data not shown) (Sasso et al. 2018). 
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Level of expression (%) of each target on human lymphocytes 
 
 
 
Table 2. Expression profile (% of the positive cells) of each target on 
human lymphocytes. Percentage of expression was calculated as an average 
of the fraction of human lymphocytes expressing each target from 8 
different donors untreated or activated at different time intervals. Standard 
Deviations ≤ 10% (Sasso et al. 2018).  
 
Immune 
checkpoints
Untreated 
hPBMCs
(24h) activated 
hPBMCs
(96h) activated 
hPBMCs
TIM-3 0,8 20 65
BTLA 47 33 40
TIGIT 11 17.5 24
OX-40 2 67 86
4-1BB 1 53,5 70
CD-27 36 28 60
ICOS 3 32 90
PD-1 11 52 95
PD-L1 7 90 99
LAG-3 1 53 59
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Figure 15. FACS analysis of expression of immunomodulators on 
human lymphocytes untreated or stimulated for different time intervals. 
Representative FACS analyses of time course of activation for the indicated 
immune checkpoints on human lymphocytes. Lymphocytes were identified 
by analyzing the forward (FSC) versus side (SSC) scatter and gated to 
exclude debris. The live cells only were considered to measure the 
percentage of positive cells corresponding to the fraction of double positive 
population (fluoresence intensity range of 10
2
-10
5
) for both the expression of 
CD2 (the T-Lymphocytes lineage marker) and of the specific target of 
interest: LAG-3 (A), PD-L1 (B), PD-1 (C), TIM3 (D),  BTLA (E), TIGIT 
(F), OX40 (G), 4-1BB (H), CD27 (I) or ICOS (L). Unstained cells or cells 
treated with the appropriate isotype control were used as background control 
(Sasso et al. 2018). 
 
 
 
2.2 Identification of enriched scFv sequences by next-generation 
sequencing and conversion into mAbs 
To identify individual phage clones selected by the combined 
ex vivo/in vitro approach, we decided to sequence the VH regions of 
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the IC-specific repertoires by massive parallel sequencing on the 
MiSeq Illumina platform (see Methods Section for details). To this 
aim, DNA from each repertoire of each selection cycle was extracted 
and then digested with suitable restriction enzymes to extract the 
inserts encoding scFvs. High-throughput sequence analyses of the 
whole set of selections was performed in collaboration with the 
research group of Professor N. Zambrano from our Department of 
Molecular Medicine and Medical Biotechnology.  
As a proof of concept of the quality/potency of the binders 
identified by this novel approach, the scFv sequences that were 
specifically enriched after panning on three targets, i.e., LAG-3, PD-1 
and PD-L1, were chosen for further studies. Indeed, antibodies 
specific for two of these targets, such as anti-PD-1 Nivolumab and 
anti-PD-L1 Atezolizumab, have been previously developed and 
widely used in the clinic, and thus they can be used for comparison in 
biological assays. Starting from the most enriched sequences for each 
of the LAG-3, PD-1 and PD-L1 IC-specific repertories, we 
accomplished the rescue of the corresponding scFvs (as described in 
Methods). The conversion of scFvs into more stable antibody formats 
(IgG4 isotype) was carried out by subcloning the variable regions into 
two eukaryotic vectors for the expression of H and L chains and by 
transfecting the resulting recombinant vectors into HEK293-EBNA 
cells. This task was carried out in collaboration with the research 
group of Professor N. Zambrano (Sasso et al. 2018). 
 
2.3 Human IgGs generated from selected binders show high binding 
affinity and receptor/ligand competitive activity 
Human IgG4 antibodies generated from the best ranking LAG-
3, PD-1 and PD-L1 binders were confirmed to recognize human 
activated PBMCs and recombinant proteins with low nanomolar or 
sub-nanomolar affinity (see Figure 16, Table therein, and Figure 
17). In particular, some anti-PD-1 mAbs (i.e., PD-1_1 and PD-1_2) 
showed comparable or higher apparent affinity compared to the 
clinically validated Nivolumab. Most of the anti-PD-1 and anti-PD-L1 
antibodies, including Nivolumab, displayed similar binding to the 
recombinant protein compared to the activated hPBMCs, while the 
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anti-LAG-3 antibodies showed higher affinity for the activated 
hPBMCs. Two or three of the original five antibodies chosen were 
used for further characterization because they were highly specific for 
both recombinant targets and activated lymphocytes, whereas they 
showed no or poor binding to Fc or untreated lymphocytes (see 
Figure 16 and 17). The other IgG4 were discarded because they 
recognized the Fc or not activated lymphocytes (data not shown). As 
for the anti-LAG-3 scFvs selected by the conventional strategy on 
purified recombinant protein only and screened by ELISA assays, 
only a low percentage (15%) of positive clones contained a cDNA 
sequence encoding the whole scFv (with no stop codons or other 
rearrangements). The few clones expressing the whole scFvs were 
converted into human IgG4, and were found to be capable of binding 
to the purified protein, but they recognized the activated lymphocytes 
with lower affinity (data not shown). Furthermore, some of them 
were found to be unstable during their storage at 4°C for 2-4 days, 
thus they were not used for further characterization.  
Because anti-PD-L1 antibodies have been shown to provide 
for clinical benefit by blocking interaction between PD-L1 expressed 
on cancer cells and PD-1 displayed by T cells (Shultz 2017), we 
tested whether the anti-PD-L1 antibodies would also recognize their 
targets on the surface of cancer cells. All anti-PD-L1 antibodies 
showed high affinity for tumor cells expressing PD-L1, such as 
mammary MDA-MB-231 tumor cells, and the hierarchy of binding 
activity to tumor cells was similar to that observed with activated 
hPBMCs (Figure 16 and Table therein) (Sasso et al. 2018). 
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Figure 16. Binding of the selected antibodies to the purified 
recombinant proteins and tumor cells. Binding curves of the antibodies to 
each target protein/Fc (black curves) or Fc (grey curves) are reported in the 
left and central panels. The binding curves of the anti-PD-L1 mAbs to 
MDAMB231 cells (black curves) or MCF-7 cells (grey curves) are reported 
in the right panel. The Kd values obtained from the binding curves of the 
antibodies to each target protein/Fc, activated hPBMCs and tumor cells are 
reported in the table. Binding values were reported as the mean of at least 
three determinations obtained in three independent experiments. Error bars 
depicted means ± SD. (Sasso et al. 2018). 
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Figure 17. Binding affinity of the selected antibodies for lymphocytes. 
The ELISA assays were performed with the anti-PD-1, anti-PD-L1 and anti-
LAG-3 mAbs (obtained after the three cycles of selection) used at increasing 
concentrations (7.5 nM, 25 nM, 50 nM, 100 nM) on activated hPBMCs 
(black curves) or untreated hPBMCs (grey curves). Binding values were 
reported as the mean of at least three determinations obtained in three 
independent experiments. Error bars depicted means ± SD. (Sasso et al. 
2018). 
 
 
2.4 High affinity IgGs against immune checkpoint molecules display 
T cell immunostimulatory activity  
Previous reports showed that CD3-positive primary resting 
cells in unfractionated hPBMCs can be induced to proliferate in vitro 
by using Staphylococcal enterotoxin B (SEB) or (phytohemagglutinin 
(PHA), and that this activity is modulated by CI (Selby et al 2016; 
Wang et al. 2014; Maçon-Lemaître and Triebel 2005). We 
therefore used this assay to test whether the selected antibodies 
against LAG-3, PD-1 or PD-L1 were able to increase cell division. To 
this end, some mAbs among those with the highest affinity and 
specificity were tested for their biological activity in a flow 
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cytometry-based lymphocyte proliferation assay that allows 
identification of proliferating T cells by anti-CD3 staining. 
With this aim, CFDA-SE-stained lymphocytes were stimulated 
with PHA, and incubated in the absence or presence of the antibodies 
to induce T cell proliferation. In this assay, Nivolumab consistently 
led to a 50% increase in proliferative activity and the anti-PD-1 
antibodies PD-1_1 and PD-1_2 were also able to efficiently stimulate 
T cell proliferation with the former showing higher activity than 
Nivolumab (Figure 18A). Similarly, all three antibodies against PD-
L1 and one of the three LAG-3 antibodies also induced various 
degrees of proliferation. The ability to stimulate proliferation did not 
always correlate with the binding potency, suggesting that the 
different antibodies may have distinct modes of interactions with their 
targets. The antibodies PD-1_1 and PD-L1_1 that were the best 
activating antibodies on human lymphocytes confirmed this ability 
also on murine lymphocytes (Figure 19), thus suggesting that they are 
cross-reactive with mouse PD-1 and PD-L1. 
We used MDA-MB-231 breast tumor cells, which express 
high levels of PD-L1 on their surface, to test the ability of the anti-
PD-L1 and anti-PD-1 antibodies to suppress the inhibitory action of 
the PD-1/PD-L1 interaction on lymphocyte proliferation when the two 
cell types are co-cultured. As shown in Figure 18B, mAbs PD-L1_1 
and PD-1_1 induced the proliferation of lymphocytes in a dose-
dependent manner, whereas only a slight effect was detected on 
lymphocytes treated with mAbs PD-L1_2 and PD-1_2 (data not 
shown). Also in this assay mAbs PD-L1_1 and PD-1_1 displayed 
higher activity than Nivolumab, while no effects on the proliferation 
of lymphocytes were observed when PD-L1-negative MCF-7 tumor 
cells were used. In competition ELISA assays, we showed that mAbs 
PD-L1_1 and PD-L1_2 were able to interfere with the recognition of 
PD-L1 by its two receptors PD-1 and B7.1 (Figure 20). 
However, we suppose that these novel antibodies could act not 
only by interfering in PD-1 and PD-L1 interaction, but also by other 
antagonistic effects on their receptors or ligands. Indeed, it is likely 
that PD-1_1 has a different mechanism of action with respect to that 
of Nivolumab. This hypothesis is based on the results obtained by 
competitive ELISA assays, performed by measuring the binding to 
immobilized PD-1 of biotinylated Nivolumab in the absence or in the 
presence of saturating concentrations of unlabelled PD-1_1 and PD-
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1_2 mAbs. As shown in Figure 21, the binding curves of biotinylated 
Nivolumab in the absence or in the presence of PD-1_1 or PD-1_2 
mAbs are superimposable, thus suggesting that the novel PD-1_1 and 
PD-1_2 mAbs do not interfere with Nivolumab in the interactions 
with PD-1 receptor (Sasso et al. 2018). 
 
Figure 18. Effects of the novel antibodies on lymphocyte proliferation. 
A: Proliferation of hPBMCs after stimulation with PHA at 2.5 μg/ml in the 
absence or in the presence of the immunomodulatory mAbs. Fold increase of 
CD3
+ 
T cell proliferation determined by the indicated selected antibodies 
was measured by anti-CD3 staining by FACS with respect to activation of 
hPBMCs with PHA in the absence of antibodies or in the presence of an 
unrelated IgG4. B: Effects of anti-PD-L1 antibodies on Lymphocyte 
proliferation as induced by tumor cells. Fold increase of hPBMCs 
proliferation as determined by normalized absorbance values obtained by 
ELISA with anti-BrdU antibodies in hPBMCs samples co-cultured with 
MDA-MB-231 (left panel) or MCF-7 (right panel) tumor cells in the 
absence (white bar) or in the presence of increasing concentrations (50 nM 
and 200 nM) of PD-L1_1 (light grey bars) or PD-1_1 (grey bars) antibodies 
for 72 hours at 37°C. Nivolumab was used, in both the experiments, as a 
positive control (black bars). Concentration values were reported as the 
mean at least three determinations in five independent experiments 
performed by using lymphocytes from 5-8 healthy donors. Error bars 
depicted means ± SD. P values for the indicated mAbs relative to unrelated 
IgG4 are: ***P ≤ 0,001; **P < 0,01; *P < 0,05 (Sasso et al. 2018). 
Results 
 55 
 
Figure 19. Proliferation of mouse PBMCs after stimulation with PHA at 
2.5 μg/ml in the absence or in the presence of the immunomodulatory 
antibodies. Fold increase of CD3-T cell proliferation determined by the 
indicated selected antibodies was measured with respect to activation of 
mouse PBMCs with PHA at 2.5 μg/ml in the absence of antibodies or in the 
presence of an unrelated IgG4 (10μg/ml). Concentration values were 
reported as the mean at least three determinations in five independent 
experiments performed by using lymphocytes from 5-8 healthy donors. 
Error bars depicted means ± SD. P values for the indicated mAbs relative to 
unrelated IgG4 are: ***P ≤ 0.001; **P < 0.01 (Sasso et al. 2018). 
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Figure 20. Competitive binding assays. Competitive ELISA assays were 
performed by testing the binding of the biotinylated chimeric proteins PD-
1/Fc (panel A) or B7.1/Fc (panel B) to PD-L1 in the absence (white bars) or 
in the presence of the unlabeled competitive PD-L1_1 and PD-L1_2 
antibodies (grey bars). In both the experiments the binding of the novel PD-
L1_1 and PD-L1_2 antibodies to PD-L1 chimeric protein was tested as a 
control in parallel assay (panels C and D). Binding values were reported as 
the mean of at least three determinations obtained in three independent 
experiments. Error bars depicted means ± SD. P values for the indicated 
mAbs relative to control are: ***P ≤ 0.001 (Sasso et al. 2018). 
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Figure 21. Competitive ELISA assay of PD-1_1 or PD-1_2 mAbs with 
biotinylated Nivolumab (Nivolumab-B). Competitive ELISA assays were 
performed by measuring the binding of Nivolumab-B to PD-1 at the 
indicated concentrations (1, 3, 5 and 10nM) in the absence (black curve) or 
in the presence of the unlabeled PD-1_1 (red curve) or PD-1_2 (green curve) 
mAbs used at saturating concentration (400nM), respectively. In a parallel 
assay, the binding of Nivolumab-B was tested in the presence of the 
unlabeled Nivolumab (grey curve) at the same saturating concentration. 
Binding values were reported as the mean of at least three determinations 
obtained in three independent experiments. Error bars depicted means ± SD. 
 
  
2.5 Effects of the novel high affinity IgGs against immune 
checkpoint molecules on secretion of cytokines 
Immunomodulatory antibodies, such as Nivolumab, 
Ipilimumab and Pembrolizumab were shown to improve T cell 
effector functions, with this property potentially increasing their 
clinical benefit (Maçon-Lemaître and Triebel 2005; Wang et al. 
2014; Selby et al. 2016).  
We therefore tested five antibodies among those with the 
highest ability to induce T cell proliferation (LAG-3_1, PD-1_1, PD-
1_2, PD-L1_1, and PD-L1_2) in a cytokine secretion
 
(Sanmamed et 
al. 2015) assay previously reported for the characterization of 
Nivolumab (Wang et al. 2014). In this assay, we included 
Atezolizumab as an additional positive control (Patel et al. 2017; 
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Shultz 2017). As shown in Figure 22, all the tested antibodies were 
able to increase the secretion of both IL-2 and interferon IFNγ by 
hPBMCs stimulated with either PHA or SEB. Cytokine secretion 
increased over time upon addition of the different antibodies to the 
cell culture mixture. PD-1_1 mAb appeared to be consistently more 
potent than all the other tested antibodies for its ability to stimulate 
secretion of both cytokines. Also, in this assay most of the newly 
identified antibodies compared well with Nivolumab and 
Atezolizumab, further supporting the conclusion that the Immunome 
Library that we generated is enriched in binders with good potential 
for being developed for clinical use (Sasso et al. 2018). 
 
 
Figure 22. Effects of the novel immunomodulatory antibodies on 
secretion of cytokines by stimulated T cells. IL-2 and IFNγ values 
obtained by ELISA assays on supernatants of hPBMCs stimulated with PHA 
(2.5 μg/mL) or SEB (50 ng/mL) in the absence or in the presence of the 
antibodies LAG-3_1, PD-1_1, PD-1_2, PD-L1_1, PD-L1_2 at the 
concentration of 20μg/ml for 18-66 hours at 37°C. Nivolumab, 
Atezolizumab and an unrelated antibody were used as a positive and 
negative control, respectively. Concentration values were reported as the 
mean at least three determinations in five independent experiments 
performed by using lymphocytes from 5-8 healthy donors. Error bars 
depicted means ± SD (Sasso et al. 2018). 
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2.6 In vivo antitumor activity 
The two antibodies PD-1_1 and PD-L1_1, given their cross-
reactivity with mouse PD-1 and PDL1, were also tested in vivo on the 
CT26 colon cancer model in collaboration with the research group of 
Professor A. Nicosia from our Department of Molecular Medicine and 
Medical Biotechnology. Mice were implanted with CT26 cells (day 0) 
and then treated with PD-1_1 and PD-L1_1 antibodies (day 3, 6, 10). 
Two commercially available antibodies reacting against murine PD-1 
and PD-L1 (α-mPD-1 and α-mPD-L1), and previously validated in 
vivo, were used as positive controls (Wang et al. 2016). While the 
growth rate of tumors in untreated mice was very fast and 
uncontrolled, with the majority of tumors reaching sizes of > 650 mm
3
 
at day 21, a reduction in tumor volume was found in mice treated with 
PD-1_1 (p=0.03). The activity of the cross-reactive anti-PD-1 
antibody is comparable to that of the commercial antibody against 
murine PD-1. A trend of comparable activity was also observed for 
the two anti-PD-L1 antibodies (Figure 23). Treated mice consistently 
show a dichotomy in the response to PD-1 and PD-L1 blockade with 
two distinct treatment outcomes, responder and non-responder mice, 
as well described for this and other cancer models. During the period 
of treatment, the animals did not show signs of wasting or other 
visible signs of toxicity. Thus, the biological and functional activity of 
the two novel mAbs was also confirmed in a relevant in vivo model 
(Sasso et al. 2018). 
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Figure 23. In vivo antitumor activities of PD-1_1 and PD-L1_1 
antibodies. Tumor growth in groups of 10-12 mice inoculated with CT26 
cells at day 0 and treated with PD-1_1, PD-L1_1 or positive control 
antibodies reacting against murine PD-1 and PD-L1 (α-mPD-1, α-mPD-L1) 
at day 3, 6 and 10. Shown is tumor volume for individual mice at day 21 
(left) and mean of tumor volume for each group over time (right panel) 
(Sasso et al. 2018). 
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DISCUSSION AND CONCLUSIONS 
 
During the past three decades, anticancer immunotherapy has 
evolved as an encouraging therapeutic option and a number of 
immunotherapeutic drugs have been approved by the FDA for clinical 
use. Furthermore, many innovative therapeutic regimes, involving the 
combination of new drugs with conventional treatments, are being 
designed and tested in clinical trials with promising results (Galluzzi 
et al. 2014).  
Tumor-targeting monoclonal antibodies, endowed with 
intrinsic antineoplastic activity, belong to the passive form of 
immunotherapy, whereas antibodies targeting immune regulatory 
checkpoints, employing anticancer effects only upon the engagement 
of the host immune system, belong to the active form of 
immunotherapy (Galluzzi et al. 2014; Papaioannou et al. 2016). 
  
 
1.  Immunotherapy based on novel human  immunoagents specific 
for TAAs 
 
The current trends for the use of antibodies in oncology are to 
employ them alone or in combinations as therapeutic agents. The 
specific and direct inhibition of the signal transduction of receptors, 
expressed on tumor cells (Wurz et al. 2016) and involved in tumor 
cell survival and proliferation, with a combination of antibodies 
against distinct noncompeting epitopes is a strategy widely tested 
(Riccio et al. 2017).  
ErbB2 overexpressed in breast cancer and in many other 
carcinomas represents an attractive target for immunotherapy 
(Slamon et al. 1989; Tagliabue et al. 1991; Lohrisch and Piccart 
2001; Gravalos and Jimeno 2008), and Trastuzumab was the first 
humanized monoclonal antibody to become standard of care for 
metastatic ErbB2-positive breast cancer (Riccio et al. 2017). 
However, some ErbB2-positive tumors are resistant to Trastuzumab, 
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thus another humanized anti-ErbB2 antibody, named Pertuzumab, has 
been recently approved by FDA. Since they have different 
mechanisms of action, as they bind to the domain II and the domain 
IV of ErbB2 respectively, they can be combined showing superior 
antitumor activity compared to single agent treatments (Sabatier and 
Gonçalves 2014; Stebbing et al. 2000; Romond et al. 2005; Baselga 
and Swain 2010). These findings led to the preclinical evaluation of 
cocktails of noncompeting antibodies (Riccio et al. 2017), but an 
important limit was still represented by the increasing cost of 
treatment. 
Furthermore, recently in literature a triparatopic construct 
targeting EGFR has been reported, which showed superior activity 
with respect to combination of noncompetitive antibodies, mainly 
attributed to better matrix induction and increased degradation of 
EGFR (Riccio et al. 2017). On the basis of these observations, we 
decided to characterize for the first time a triparatopic immunoagent 
targeting ErbB2/HER2. To this aim a Tribody format, obtained by 
genetic fusion of the genes for either the Fab Fd-chain or L chain with 
the genes of 2 distinct scfv molecules, was used. The trispecific 
Tribody is an antibody construct (100 kDa) with a lower molecular 
size than a whole IgG and well suited for both tumor penetration and 
acceptable half-life (Riccio et al 2017). The Tribody, named TbTPE, 
was designed to contain three binding sites recognizing three distinct 
non-overlapping epitopes of ErbB2, derived from Erb-hcAb, 
Pertuzumab and Trastuzumab. We show here that the triparatopic 
Tribody TPE is able to bind to all the ErbB2-positive tumor cells 
tested, to downregulate ErbB2 on ErbB2-positive tumor cells, and to 
inhibit tumor growth more efficiently than the trivalent 
monoparatopic controls (Tb-TTT, Tb-PPP, Tb-EEE), or compared 
with a combination of 3 different bivalent monoparatope monoclonal 
antibodies, recognizing different epitopes of the receptor. 
Interestingly, the multiparatope Tribody Tb-TPE is able to affect also 
the growth of Trastuzumab-resistant tumor cells, such as the MCF7-
HER2Δ16 or JIMT-1 cells, by dramatically reducing the level of 
ErbB2, thus providing a useful tool to overcome resistance. 
This novel construct has the following advantages: it combines 
in 1 single molecule 3 different targeting approaches and antitumor 
actions of 3 different antibodies, such as Trastuzumab, Pertuzumab 
and Erb-hcAb; it can be used for a larger patient population due to its 
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ability to overcome the tumor heterogeneity; it allows to reduce the 
costs of antibody production as only 1 construct provides the effects 
of 3 different antibodies. 
 
 
 
2. Immunotherapy based on immunomodulatory mAbs 
The other antibody-based approach in oncology is represented 
by the immunomodulatory mAbs that operate by interacting with 
soluble or cellular components of the immune system, to elicit a 
novel, or prolong an existing anticancer immune response (Galluzzi 
et al. 2014; Peggs et al. 2009). The first mAbs recently approved by 
FDA for this approach include three classes of immune checkpoint-
blocking mAbs for clinical treatment of a variety of solid tumors: 
Ipilimumab (anti-CTLA4 mAb), Pembrolizumab and Nivolumab 
(anti-PD-1 mAbs) and Atezolizumab, Durvalumab and Avelumab 
(anti-PD-L1 mAbs) (Galluzzi et al. 2014; Brahmer et al. 2012; 
Patel et al 2017; Shultz 2017; Callahan et al. 2016). However, the 
efficacy of these checkpoint inhibitors is still limited to 20–30% of the 
population, and could not be shown in highly prevalent cancer types 
(Lee et al. 2013; Pardoll 2012; Buqué et al. 2015; Anderson et al. 
2016). Interestingly, the combination of anti-PD-1 and anti-CTLA-4 
antibodies, resulted in a longer higher rate of response with respect to 
that observed with the single mAb treatments in metastatic melanoma 
and MSI-associated colorectal cancer (Mahoney et al. 2015; Larkin 
et al. 2015), thus indicating that proper combination of different 
antibodies could be essential to achieve a more effective immune-
based cancer therapy. Thus, further progress in the field could be 
represented by the generation of a complete repertoire of fully human 
antibodies specific for many immune checkpoints to be tested, either 
alone or in appropriate combinations for rapid translation into the 
clinic (Sasso et al . 2018).  
With this aim, a novel selection strategy by phage display on 
live hPBMCs was performed to obtain an unbiased library of immune 
checkpoint binders. This strategy consisted in a negative panning on 
untreated hPBMCs to remove all the non-specific binders, followed 
by a positive panning on activated hPBMCs to collect only the scFvs 
specifically binding to receptors expressed on activated lymphocytes. 
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For the following identification of the clones specific for each target, 
we combined the ex vivo/in vitro selection with the Next-Generation 
Sequencing approach for a more rapid and efficient selection with 
respect to the conventional strategy, carried out by panning on the 
purified protein only and followed by screening with ELISA assays. 
Using this novel strategy, we rapidly identified more stable human 
IgG4 antibodies, endowed with biological activity, and able to 
recognize the cell-displayed receptors with apparent affinity in the 
low nanomolar range and down to 0,1–0,4 nM. This binding affinity 
is well within what has already been shown with clinically active 
checkpoint-specific antibodies, and compares well with that of the 
clinically approved Nivolumab (Sasso et al. 2018).  
As a proof of concept in this thesis work we further 
characterized the antibodies specific for PD-1, PD-L1 and LAG-3. 
The choice of these three targets was based on the observation that 
selections on them gave rise to median levels of enrichment, and on 
the availability of antibodies specific for two of these targets to be 
used for comparison in well established in vitro assays to evaluate 
their functional activity. From the list of the top 10 ranking scFv 
sequences, at least 5 effective antibodies for each of these three targets 
were converted into IgG4 and found to be expressed at satisfactory 
levels, stable in solution and capable of binding to their targets. 
Overall, as indicated in the results, from the total converted IgGs 
eleven of them displayed low nanomolar apparent affinity for their 
cognate receptor expressed on hPBMCs, with PD-L1_2, PD-1_1 and 
PD-1_2 mAbs endowed with a sub-nanomolar apparent affinity 
comparable to that of Nivolumab. 
Among them, at least 2–3 of the 5 converted antibodies for 
each target were found to be highly specific for both recombinant 
purified targets and activated lymphocytes, with no significant 
binding to untreated lymphocytes or Fc, and thus they were chosen for 
further biological and functional assays. When tested for their ability 
to stimulate T cell proliferation LAG-3_1, PD-L1_1, PD-L1_2, PD-
L1_3, PD-1_1 and PD-1_2 mAbs did show biological activity and in 
particular the PD1_1 mAb was found to perform better than the 
clinically approved Nivolumab. PD-1_1 also displayed significant 
activity in promoting T cell proliferation in co-cultures with high PD-
L1-expressing tumor cell line MDA-MB-231. In this assay also the 
PD-L1_1 mAb almost tripled T cell proliferation, consistently with its 
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ability to interfere with PD-L1/PD-1 interaction. We further 
demonstrated that some of the selected antibodies can stimulate T 
cells to secrete IL-2 and IFNγ, confirming the observation that some 
of the antibodies identified in this work display binding affinities and 
biological properties similar to the clinically validated Atezolizumab 
and Nivolumab (Wang et al. 2014; Wang et al. 2016; Selby et al. 
2016). Due to the property of PD-1_1 and PD-L1_1 mAbs to cross-
react with mouse lymphocytes, differently from Nivolumab, they 
were tested in vivo and found to efficiently inhibit tumor growth 
without apparent toxic effects on mice bearing CT26 colon carcinoma 
(Sasso et al . 2018).  
Further studies are needed to carefully monitor auto-immune 
side effects, potentially induced by these antibodies, however, due to 
their high affinity; they could allow to reduce the therapeutic doses 
and the consequent eventual unwanted side effects. Moreover, the 
data presented in this work support the conclusion that our selection 
procedure allows for the generation of antibodies specifically 
recognizing their target receptor in its native conformation and with 
high affinity without need for further affinity maturation. 
Furthermore, considering the ability of the novel identified 
antibodies to stimulate T cell proliferation and display effector 
functions in a manner comparable to, or even superior than, 
Nivolumab, which has shown clinical activity in different type of 
cancer diseases, this study suggests that the ‘Immunome Library’ 
generated in this project is enriched in binders with good potential for 
being developed for clinical use. 
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